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DETERMINATION OF DYNORPHINS AND TNF- a BY LC-MS/MS IN

BIOLOGICAL SAMPLES: APPLICABLE TO STUDYING INFLAMMATORY

MECHANISMS
KARTHIK CHANDU

ABSTRACT

Dynorphins are endogenous opioid peptides that have been implicated as initiators
of immune and inflammatory response through upregulation of inflammatory cytokine and
chemokine production, as well having a role in glutamate-induced neuro-inflammation and

neurotoxicity. Being extremely potent peptides, the physiologic concentrations of
dynorphins are very low ranging from 0.16 pg/mL during the absence of a stimulus to 23.5

pg/mL when stimulated in disease condition. Previously published HPLC-mass
spectrometry techniques have insufficient detection capabilities for quantification and
detection of dynorphins. As a result, immunoassay quantification has been the most utilized

technique for analysis of dynorphins in physiologic samples. Although being sensitive,

immunoassays have some inherent drawbacks of being complex multi-step process taking

a long time to complete, challenge with reproducibility due to the non-specific binding
interactions and the requirement of high sample volume. My dissertation focused on

developing a sensitive LC-MS/MS technique to overcome such challenges in the analysis.
A sensitive and robust LC-MS/MS assay has been developed and validated in the present
work which can quantify the dynorphins below their low physiologic concentrations in

mouse serum. To achieve this level of sensitivity, the intact peptide was digested using a
novel metalloendopeptidase called Lys-N. This digestion process produced fragments

which are extremely sensitive to detection by mass spectrometer and very specific to

vi

dynorphin B. Sensitivity achieved by this method is 800 times more than previously

published HPLC-mass spectrometry techniques.
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CHAPTER I

INTRODUCTION

1. Background
Dynorphins are classified as endogenous opioid peptides [1-3] which bind
preferentially to the k-opioid receptors [2] and are formed from the 26 KDa precursor

protein prodynorphin [4,5]. Prodynorphin is found in gut, posterior pituitary, and brain [6
9]. Immunoreactivity experiments in a hamster showed its presence in the hippocampal
formation, lateral septum, bed nucleus of the stria terminalis, smedial preoptic area, medial

and central amygdaloid nuclei, ventral pallidum, substantia nigra, and numerous

hypothalamic nuclei [10]. All the bioactive peptides that are formed are the C-terminal

extensions of [Leu]enkephalin peptide sequence [11,12].
The endoproteolytic processing of prodynorphin is carried out by two primary
protease pathways. The two pathways are cathepsin L cysteine protease in secretory

vesicles and proprotein convertase 2 (PC2) proteases. This proteolysis of prodynorphin
releases dynorphin A, dynorphin B, a-neoendorphin, P-neoendorphin [4,5,12-14] and

leumorphin (dynorphin B 1-29) [2,15] with the amino acid sequence [16,17] of each given

in Table 1. The seventeen amino acid peptide, DYN-A(1-17) is further digested by these

1

peptidases resulting in structurally related peptides such as DYN-A (1-13), DYN-A(1-8)
and Leu-enkephalin [2,6,18,19]. More details concerning the degradation of dynorphins
are given in Section 1.3.1. The fragment dynorphin A-(1-13) is crucial for its potency [20].

The first four amino acid residues in the structure constitute the message region, and the

amino acids from 5-13 are responsible for the potency and specificity for the k-opioid
receptors [21].
Table I: Dynorphin peptides and their amino acid sequence

Peptide

Sequence

Dynorphin A

YGGFLRRIRPKLKWDNQ

Dynorphin B

YGGFLRRQFKVVT

a-neoendorphin

YGGFLRKYPK

P-neoendorphin

YGGFLRKYP

Leumorphin

YGGFLRRQFKVVTRSQEDPNAYSGELFDA

1.1. Physiologic effects of dynorphins
Dynorphins play a regulatory role in numerous functional pathways. They play a

significant role in the regulation of the immune/inflammatory system and are known to
activate immune system functions that are associated with innate immunity [22,23].

Dynorphins are ligands for k-opioid receptors and the expression of these receptors is very

well regulated in the immune system [24-29]. In addition, they can influence the
upregulation and release of monocytes/macrophages [30-32], polymorphonuclear

leukocytes [33], and as well as proinflammatory cytokines [34-36]. Dynorphins also act

2

by the stimulating the production of oxygen free radicles [33], cause neuronal cell death
by excitotoxic mechanisms altering glutamate levels, increase ion (K+, Ca+2 and Mg+2)

permeability of ion channels [37-41] and activate NMDA receptors [37,42-44].
1.2. Cytokine/chemokine release in response to dynorphins
Activation of NMDA receptors triggers a series of inflammatory interactions
beginning with the activation of NF-kB [36,45,46], followed by an upregulation in the

expression of proinflammatory cytokines such as TNF-a and IL-6 [32,47], which causes
an upregulation in the expression of chemokines such as MCP-1/CCL2 [47-49] and
proliferation of phagocytic leukocytes and lymphocytes [47,50]. Since dynorphins have
the ability to affect the activation of the NMDA receptors, they are capable of starting the

complete process of inflammatory interactions that lead to an increase in the production of

proinflammatory cytokines, chemokines, and superoxides [32,51,52].

1.2.1. Other effects
Dynorphins are endogenous neuroactive opioid peptides that are known to play a
role in a variety of physiological processes such as the regulation of pain [53-57],

temperature [58], motor activity [59,60], the cardiovascular system [61,62], respiration,
feeding behavior [63,64], hormonal balance, and responses to shock and stress [65]. The

“non-opioid” effects of dynorphins also include neurological dysfunction, cytotoxicity,

secondary tissue damage, paralysis, neural inflammation, and a potentiation of NMDA
receptor sensitivity to glutamate leading to neuropathic hypersensitivity that is often

associated with chronic peripheral tissue inflammation [37,42,57,59].
Dynorphins also act by stimulating the production of oxygen-based free radicals

[33], causing neuronal cell death by excitotoxic mechanisms that include alterations in
3

glutamate levels, and increases in ion (K+, Ca+2 and Na+) conductance’s [37,66] by way

of interactions at NMDA receptors [37,42,44]. A comprehensive review has been
published [67].
1.3. Dynorphins in physiologic samples

1.3.1. Degradation process

As previously mentioned, the proteolysis of the precursor molecule prodynorphin
releases dynorphin A, dynorphin B, a-neoendorphin, ß-neoendorphin and leumorphin

(dynorphin B 1-29)[2,15]. Among the dynorphins, dynorphin-B, as well as dynorphin-A
(1-17) are relatively less susceptible to proteases [68] in normal physiological conditions.
There are multiple kinds of peptidases that metabolize the dynorphin peptides. A few of

the major peptidases involved are aminopeptidases [69], angiotensin-converting enzyme
(ACE), insulin degrading enzyme [70], serine peptidases [71], dipeptidyl peptidase III and
IV (DPP III, DPP IV) [72], which act to either convert a parent peptide sequence into an

active form or to inactivate a physiologically active peptide [73,74].
Dynorphin A (1-17) has been shown to undergo very slow biotransformation and
the products formed depend on the site at which it is released. It has been shown that rat

brain, human and rhesus monkey blood show common product peptides after its

metabolism [75]. During the initial 30 minutes, dynorphin A metabolized to dynorphin A

(2-17) , dynorphin A (3-17), dynorphin A (4-17), dynorphin A (5-17), dynorphin A (1-6),
dynorphin A (7-17), dynorphin A (8-17), and dynorphin A (9-17). After a prolonged
incubation time of 1 to 4 hours, it metabolized to dynorphin A (3-17), dynorphin A (4-17),
and dynorphin A (5-17) [76-78].
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Dynorphin A (1-13) has a very fast biotransformation rate, with the initial sequence
metabolizing in 0.5-1 minute. A 30 min incubation period produced products such as

dynorphin A (1-12), dynorphin A (4-12), dynorphin A (3-12), dynorphin A (2-12),
dynorphin A (1-6), dynorphin A (5-11), and dynorphin A (5-12) [73,78].

1.3.2. Physiological concentrations
Being extremely potent, dynorphins are present in a very low concentrations in
normal physiologic samples. Its concentration increases only in response to certain
physiological stimuli. The concentrations of dynorphins varies with the type, location of
the peptides and condition of the body (normal or stressed). The concentration of
dynorphin-B in human serum can range from 0.16 pg/mL during the absence of a

physiological stimulus to 23.5 pg/mL when stimulated by disease processes [32,33,79]. As

these are very potent peptides, the increase in the physiological concentration when
provoked, is relatively still low.

The concentrations of different dynorphins vary in different locations in the body.

DYN-A(1-13) is capable of stimulating the production of cytokines such as TNF-a and
IL-6 at a concentration of 0.16 pg/mL [32] and mediates the chemotaxis of macrophages

at concentrations as low as 0.16 pg/mL, with peak effects observed at concentrations of
16.0 pg/mL to 16.0 ng/mL [31]. A concentration of 25.0 pmol/g was found in the substantia

nigra and hypothalamus, whereas the other parts of the human post-mortem brain such as

amygdala, hippocampus, periaqueductal grey, colliculi, pons, medulla and area postrema
showed a relatively lower concentration [2].

5

1.4. Quantification techniques

1.4.1. Non-spectroscopic techniques
Immunoassay quantitation is the most utilized technique for determination of
dynorphins at physiologic concentrations [34]. Immunoassays have been used extensively

to analyze dynorphins for many years. Immunoassays use an antibody coated surface
(usually a microplate or a microsphere) which is specific to the dynorphin of interest to
capture the peptide and then another antibody specific to another site on the peptide called

a reporter molecule is used to quantify the peptide present by comparing to a reference
standard curve.
Though immunoassays have been used in the past, they have a few drawbacks [80]

such as:
1. It is a complex multi-step process based on a biological reaction between an antibody

an antigen. Such reactions have an inherent issue of a lack of reproducibility due to

non-specific binding, lot to lot variability in the antibody plates/microspheres used.

These drawbacks lead to false positive and inconsistent results.
2. As the process involves multiple steps, the analysis takes a very long time to complete.
3. Due to the use of specific antibodies, it is not possible to differentiate and analyze

multiple species of dynorphins at the same time.

Having such drawbacks warrants the requirement for a method which can not only
overcome the challenges but also enhance the effectiveness and quality of analysis.

6

1.4.2. Mass spectrometry in the analysis of dynorphins
LC-MS as a tool for the analysis of dynorphins. LC-MS has an advantage when
compared to immunoassays [80-82] due the fact that they are
1. Very robust and highly reproducible.

2. Extremely sensitive and precise
3. Requires very little sample for analysis

4. The process is majorly automated, thus reduces the possibility of human errors and

can analyze multiple samples in a short period of time.
5. Multiple analytes can be differentiated and quantified at the same time

Being automated, LC-MS when coupled with informatic tools, has the capability to

run and analyze multiple samples in minutes.

1.4.3. Current mass spectrometry technique to analyze dynorphins
Although in the past, LC-MS/MS, MALDI-IMS (imaging mass spectroscopy) and

MALDI-TOF methods were developed and afforded the advantage of providing the
simultaneous determination of individual dynorphins [83-87], none of these methods were

established to quantify the very low physiological concentrations of dynorphins. The
current project is focused on the development of a very sensitive LC-MS/MS method for
the separation and quantification of all the dynorphins, a-neoendorphin and cytokines.
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CHAPTER II

OVERVIEW OF LC-MS TECHNIQUES FOR QUANTIFYING PROTEINS AND
PEPTIDES

2.1. Introduction to mass spectrometry for biomolecules

A mass spectrometer has three major components: an ion source (ionization of the
analytes), mass analyzer (filters the ions based on mass-to-charge ratio) and a detector
(produces signal that can be recorded). There are many different types of mass analyzers

such as quadrupole, ion trap, time of flight and Fourier transform (ion cyclotron and

orbitrap), and orbitrap. The choice of mass analyzer depends on the mass of the analyte,
required resolving power, compatibility with desired ion source and desired limit of

detection. The pros and cons of a few commonly used different mass analyzers are shown
in Table II.

Mass spectrometry-based proteomics has an important technique for the qualitative

and quantitative analysis of proteins and peptides in the field of bio-analysis.

Over the past decade, the technique has been developed with a major focus on the
technological aspects of mass spectrometers to allow the quantification of proteins and

peptides with the required accuracy, selectivity, and sensitivity [88]. This technique is now
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being utilized at almost every stage of bio-molecule analysis starting from formulation
development, stability studies, structural characterization (amino acid sequence, molecular

weight, post-translational modifications and modification sites) and quality control.
Due to their large molecular weights, biomolecules such as proteins and peptides
usually require high mass range and high-resolution instruments with MS/MS capabilities

such as a quadrupole time-of-flight (Q-ToF) instrument or a more advanced hybrid orbitrap
MS system. MS/MS is a process in the mass spectrometry which is used to obtain structural
information for the proteins and peptides of interest. A wide range of fragmentation

techniques such as collision-induced dissociation (CID), higher-energy collision
dissociation (HCD), electron capture dissociation (ECD) and electron transfer dissociation

(ETD) are used for MS/MS experiments. Collision-induced dissociation (CID) is the most
used technique, with the fragmentation pattern of peptide bonds in proteins and peptides
shown in Figure 1.
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Figure 1: Fragmentation patterns from CID producing b ions and y ions
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Table II: Pros and cons of commonly used mass analyzers [89-93]
S.No.

Mass
analyzer

1

Quadrupole

2

Time of flight

3

Ion trap

5

Orbitrap

Pros and cons
Pros :
• Rugged, Reliable, and Sensitive
• Less maintenance
• Very rapid scan rate
Cons :
• Small mass range (not very suitable for large protein
analysis)
• Low resolution
Pros:
• Highest mass range (Ideal for intact protein analysis)
• Very fast scan speed
• Excellent mass accuracy and high resolution
• Improved dynamic range for quantification (newer
instruments)
• Capable of SWATH analysis (data-independent
acquisition strategy that provides a very comprehensive
quantitative analysis)
Cons:
• Difficulty of adaption to electrospray; High maintenance
Pros :
• Simple design - Low cost; Small size; Well suited for
tandem MS; Easy for positive/negative ions
Cons :
• Limited mass range - not as much a problem with
current innovations
• Medium resolution
Pros:
• High mass range (Ideal for intact protein analysis)
• Fast scan speed
• Excellent mass accuracy and high resolution
• Capable of data-independent acquisition
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Mass spectrometers are often coupled with a variety of chromatographic
techniques. Chromatography techniques such as reversed phase and HILIC are compatible

with mass spectrometry, whereas hydrophobic interaction (HIC), ion exchange (IEX), and
size exclusion (SEC) chromatography are not directly compatible due to the use of salts

that are not volatile.
2.2. Types of protein analysis

Proteins and peptides can be analyzed by mass spectrometry either in the intact
form or as digested protein or peptides. Based on the type of analysis and the form of the

proteins being analyzed, the workflow can be categorized as intact/ top-down, middle-up,

middle-down, bottom-up.
Top down or intact protein mass spectrometry analysis gives information about the

whole protein in its primary confirmation. This approach has the potential to cover the

entire protein sequence and fully characterize proteoforms, protein forms resulting from

genetic variations and post-translational modifications [94-96].
Bottom-up proteomic analysis involves the introduction of peptides generated by

enzymatic cleavage of proteins into the mass spectrometer. The original protein is
identified by comparing MS/MS spectra of the peptides generated with the hypothetical
peptide MS/MS spectra generated based on the amino acid sequences of proteins in a
protein sequence database [96,97].
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Middle-down analysis is an emerging approach, which has the potential for

successful applications to proteomics. This approach involves the analysis of peptides
obtained by proteolysis or chemical degradation of the intact proteins. The size of the

analyzed peptides in middle down approach is greater when compared to the peptides in
bottom-up approach. This approach results in a relatively lesser number of peptides after
proteolytic cleavage in comparison to bottom-up approach leading to a less complicated
sample. Longer peptides not only have an advantage of being more unique but also achieve
an enhanced sequence coverage of the protein which would allow the detection of more

PTMs and proteoforms when compared to the bottom-up approach [96].
Each technique has its own advantages and disadvantages in terms of structural
information provided, sequence coverage, sample consumption, and ease of analysis.
Often full protein characterizations will be carried out using multiple methods due to their

complimentary nature. A brief overview of the different methods is shown in Figure 2.

Figure 2: Type of analysis and form of protein analyzed
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2.3. Sensitivity considerations for using digesting enzymes

Bottom up proteomics approach (use of surrogate peptide) has become the most

used strategy for mass-spectrometry-based protein quantification. The surrogate peptide
approach has gained popularity due to the compatibility of the small molecular weight

peptides to highly sensitive and specific triple quadrupole mass spectrometers [98,99]
2.4. Types of enzymes used in peptide and protein digestion

Proteolysis is carried out by a group of enzymes called proteases or peptidase, that

hydrolyze proteins into constituent peptides. Based on the site of action on the protein,
proteases are generally classified as exopeptidases, which target the terminal ends, or as
endopeptidases, which target internal peptide bonds. However, proteases are also classified

based on their structure and mechanism of action into six major types: aspartic, glutamic,
metalloproteases, cysteine, serine, and threonine proteases. A large number of proteases
have been identified and reported. The Degradome Database lists 569 human proteases as
shown in Table III [100-104].
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Table III: Types and number of proteases
S.No.

Type of protease

Number

1

Metalloproteases

194

2

Serine proteases

176

3

Cysteine proteases

150

4

Threonine proteases

28

5

Aspartic proteases
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Proteases and peptidases have a wide range of industrial, biotechnological and

research applications. Applications include: proteolytic digestion of proteins in proteomics
studies, peptide synthesis, nucleic acid purification by digesting unwanted proteins, cell
culture experiments, exploration of the structure-activity relationships of proteins and

peptides and peptide sequencing [105-107].
Enzymatic digestion of the intact proteins is one of the major applications of

proteases in proteomics workflow prior to mass spectrometry analysis. Different proteases
can be used for the process of digestion based on the requirement of the analysis. A list of

few commonly used proteases/peptidases is listed in Table IV [106,108].
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Table IV : List of few commonly used proteases along with their cleavage sites
S.No.

Cleavage site

Protease/peptidase
Aspartic

1

Pepsin

Phe (or Tyr, Leu, Trp)^Trp (or Phe, Tyr, Leu)

Metalloproteases

5

Lys N

¡Lys

6

Asp-N

¡Asp

Cysteine
7

Arg-C

Arg¡

Serine
9

Trypsin

Arg or Lys^

10

Chymotrypsin

Trp (or Phe, Leu, Tyr)¡

11

Glu-C

Glu (or Asp)¡

12

Lys-C

Lys¡

15

The serine protease trypsin is the most widely used enzyme to generate smaller
peptides [108,109]. Other proteases such as chymotrypsin, Lys C, Lys N, Asp N, Arg C,

and Glu C are also used in addition to trypsin in order to improve the structural
identification of proteins [110,111]. The use of proteases/peptidases produces peptides

which have a size appropriate for ionization and further detection by mass spectrometry
[112].
2.5. Factors affecting the mass spectrometry signal intensity in peptide determination

Sample size and complexity are challenges in mass spectrometry. This can be
overcome by careful and target centric sample preparation and increased efficiency of
processing. Improving efficiency is important as sample losses during processing can have

a huge impact on the sensitivity of the assay. This becomes even more important when
processing complex biological matrices due to the extremely low concentrations of analyte.

2.5.1. Instrumentation
Multiple techniques have been developed for the analysis of different kinds of
analytes (Table II). The type of instrument to be used for the analysis is decided based on
the structure and properties of the analyte. Achievement of lower limits of detection for

less abundant intact proteins in a biological sample has been realized from technological
advances in mass spectrometer instrumentation. For analysis of intact proteins, a
technology such as Fourier Transform Ion Cyclotron Resonance (FT-ICR) provides

excellent mass resolution and accuracy, however it lacks the sensitivity required for low

level detection of proteins [113]. The advent of orbitrap mass spectrometry improved the
ability to detect proteins at low levels [114]. Triple quadrupole (QQQ) mass spectrometers
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have a very high sensitivity in the determination of steroids compared to time of flight
(TOF) and quadrupole time of flight (QTOF) mass spectrometers [115]. However, QQQMS has a lower mass range which is only suitable for low molecular weight proteins and

peptide analysis.

2.5.2. Sample preparation
When dealing with protein bioanalysis, sensitivity is one of the major challenges in
MS-based assays. All biological matrices have a high abundance of endogenous

compounds. These endogenous compounds interfere with the analysis of a protein of
interest either by contributing to the background noise or by causing severe ion

suppression. This causes a significant reduction in the detection and quantification
sensitivity of an assay. An effective sample preparation process that can isolate the protein

of interest by reducing the complexity of the sample matrix is thus one of the most
important steps in the development of an assay. Many sample preparation techniques have

been developed and applied to assay development. One or a combination of different
techniques have been applied based on the type of analysis and instruments to be used.
a. Protein precipitation
One of the simplest and widely used sample preparation process is protein

precipitation which utilizes water soluble organic solvents such as acetonitrile or methanol
to precipitate out large proteins [116,117]. Apart from being simple, this technique has

advantages like the ability to remove unwanted proteins from biomatrices prior to LCMS

analysis. This process can be used for either extracting organic soluble proteins/peptides

[118,119] that are retained in the supernatant or by reconstituting the large proteins which

precipitate after addition of an organic phase [119-121].
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b. Acidified protein precipitation
This is a modified protein precipitation which is effective to remove high abundant

proteins, thereby obtaining a cleaner sample and enhancing the recovery of low abundant
proteins [122,123]. Acid-assisted protein precipitation method can efficiently remove
albumin which is one of the most abundant proteins, thus making the sample more

amenable for analysis of low abundant proteins and peptides [122].

c. Solid-phase extraction (SPE)

This technique has been used more widely in bottom-up proteomics to extract

peptides after the digestion step [119,124,125]. Solid-phase extraction is available in
multiple formats such as ion-exchange, reverse phase and mixed mode, selected based on
the characteristics of the protein/peptide to be extracted. This method has proven effective

in removing most large proteins resulting in a relatively cleaner sample to work with.
Reversed-phase SPE is used for salt removal; ion-exchange SPE is useful for separation of

small proteins and peptides and a mixed mode SPE format has specifically been used in
the purification of digested peptides in a matrix [119,125-127].

d. Immunocapture

Sample clean up and extraction of the target peptide from the matrix is one of the
major challenges in a sample preparation process. Highly efficient purification and

enrichment of the target protein can be achieved using this technique, resulting in an

improved detection limit (pg/mL) [128] of the assay [129,130]. Such efficiency makes this
the method of choice specially when working with very low abundant proteins and peptides

which require a sensitive LCMS assay with low limits of quantification. Stable-isotope

standards with capture by anti-peptide antibodies (SISCAPA) technique is one of the
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examples of immunocapture that is widely used in bottom-up proteomics to capture a

specific surrogate peptide in digested samples [129,130].
e. Selective peptide derivatization

This is a useful technique for qualitative and relative protein quantitative analysis
especially when specific immunocapture antibodies are not available for the

protein/peptide of interest. Selective surrogate peptides of the protein of interest are

derivatized, resulting in a change in the physicochemical properties of the specific target

peptides leaving the other peptides in the background underivatized. This change will result
in improved separation during extraction and chromatography, and thus enhances
sensitivity of LCMS analysis [131].
f. Mobile phase additives

Addition of low percentages (~5%) of dimethyl sulfoxide (DMSO) to mobile phase
has been employed for increased electrospray sensitivity. An increase in electrospray
efficiency and charge state reduction is due in part to the high proton affinity of DMSO in

the gas phase [132-134].

g. Fractionation and separation

A complex biological matrix can be simplified by fractionating the proteins into

different groups based on their physical and chemical properties. This technique will
reduce the background interference and improve the sensitivity of the assay. A variety of

different methods are employed based on the properties of the target analyte that needs to
be analyzed. Fractionation of proteins can be designed to separate groups of proteins
according to their size, hydrophobicity, charge, isoelectric point, or affinity as shown in

Table V [135,136].
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Table V : Fractionation methods and dependent physical or chemical property
S.No.

Fractionation method

Physical/ chemical property

1

Ultracentrifugation

Density

2

Size-exclusion chromatography

Stoke’s radius

3

Isoelectric focusing

Isoelectric point

4

Hydrophobic interaction chromatography

Hydrophobicity

5

Reversed-phase chromatography

Hydrophobicity

6

Ion-exchange chromatography

Charge

7

Affinity chromatography

Specific biomolecular interaction

8

Gel electrophoresis

Stoke’s radius

20

CHAPTER III

QUANTIFICATION OF DYNORPHINS BY LC-MS: RESULTS AND
DISCUSSION
3.1 . Analytical background:

Dynorphins are peptides which are present in a very low concentration ranging
from 0.16 pg/mL to 23.5 pg/mL in serum [32,33,79]. As these are very potent peptides, the

increase in the physiological concentration when stimulated, is relatively low.
Immunoassay quantitation is the most utilized technique for determination of dynorphins

at physiologic concentrations [34]. Although in the past, LC-MS/MS, MALDI-IMS
(imaging mass spectroscopy) and MALDI-TOF methods were developed and afforded the
advantage of providing the simultaneous determination of individual dynorphins [83-86],
none of these methods were established to quantify the very low physiological

concentrations of dynorphins. In this present work, we developed an LC-MS/MS technique
using a non-conventional peptidase for the sensitive quantification of dynorphin A,
dynorphin B and alpha-neoendorphin.
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3.2 Experimental
3.2.1 Chemicals
Dynorphin A (source; Item No. 18169) and dynorphin B (source; Item No. 18178)

were from Cayman Chemicals (Ann Arbor, MI, USA), alpha-neoendorphin from
NeoScientific (Woburn, MA, USA) and Lys-N endopeptidase from Seikagaku Corporation

(Tokyo, Japan). NSA mouse serum from Innovative research, Ammonium bicarbonate
(99% analytical grade) was from Sigma-Aldrich (Milwaukee, WI, USA), while dimethyl

sulfoxide (DMSO) (HPLC grade) and LCMS grade acetonitrile were from Fisher Scientific
(Hampton, NH, USA). Deionized water was from a Nanopore Diamond water purification

system from Thermo Scientific (city, state, USA). (missing source of human and mouse
serum).

3.2.2 Instrumentation
A Shimadzu Nexera UHPLC system (Columbia, MD, USA) with two LC-30 AD

pumps, a Prominence DUG-20A3R degasser, a SIL-30 AC autosampler, a CTO-10AVP
column oven and a CBM 20A controller interfaced with an SCIEX 5500 QTRAP mass

spectrometer source (Framingham, MA, USA). with an electrospray ionization probe and

a syringe pump was used. Instrument operation, acquisition and processing data was
performed using SCIEX Analyst software.
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3.2.3 Liquid chromatography

A gradient separation technique at room temperature was utilized to separate

dynorphin A, dynorphin B and alpha neoendorphin on a Luna Omega Polar C18 100 A LC
Column (50 x 1 mm, 1.6 pm) from Phenomenex (Torrance, CA, USA) with 0.1% formic
acid in water as mobile phase A and 0.1% formic acid in acetonitrile as mobile phase B,
pumped at a flow rate of 0.20 mL/min. For each analysis, 10 pL of sample was injected

into the system by autosampler set at 10°C. The 17 min gradient run was: 0 % B for 0.5
min, step change to 13.5% B at 0.51 min, holding at 13.5 % B for 8 min, linear gradient to

14% B in 1.5 min, linear gradient to 16% in 2 min, holding 16% B for 3 min and linear
gradient to 18% B in 2 min. After the run, the column was washed for 4 min with 80% B
and then re-equilibrated with 100% A for 10 min.

3.2.4 Tandem mass spectrometry

A positive electrospray ionization (ESI) mode was used for the mass spectrometric
analysis of dynorphin A, dynorphin B and alpha-neoendorphin. A syringe infusion pump

at 10 pL/min of Lys-N-digested peptides (10 pg/pL) in 0.1% formic acid and 15%

acetonitrile in water was introduced into HPLC effluent of the same composition resulting
in a combined flow rate of 0.2 mL/min, in order to optimize mass spectrometer parameters

at the HPLC flow rates used. Source parameters for highest signal intensity were as
follows: curtain gas 30 psi; ion spray voltage 4500 V; ion spray temperature 400°C; ion

source gases (1 and 2) 35 psi; declustering potential 35 V; entrance potential 8 V; collision
energy 40 eV and cell exit potential 10 eV.
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3.2.5 Preparation of stock and working peptide standards
Stock solution of the three peptides (dynorphin A, dynorphin B and alpha

neoendorphin) were prepared by dissolving the peptide in appropriate volume of 100 %
DMSO to obtain concentrations of 1 mg/mL. A volume of 20 uL of the stock solution was

aliquoted into 50 vials and stored at -20°C. The working standard solutions of dynorphin

A and dynorphin B (1.25, 2.5, 5, 12.5, 25, 250 pg/mL) were prepared from the stock
solution by serial dilution with 0.1% formic acid and 2% acetonitrile in water. A stock
solution of alpha-neoendorphin was also serially diluted to 50, 75, 100, 125, 250 and 500
pg/mL with 0.1% formic acid and 2% acetonitrile in water. These working standards were

then diluted with appropriate volume of pooled mouse serum to prepare the calibrators and

quality controls (QCs), as detailed below.

3.2.6 Preparation of serum calibrators and quality control
Calibrators of dynorphin A and dynorphin B (0.125, 0.25, 0.5, 1.25, 2.5, 25 pg/mL)

were prepared as described below. A volume of 20 |iL each of working standard solution

(1.25, 2.5, 5, 12.5, 25, 250 pg/mL) of the peptides was spiked into 180 uL of pooled mouse
serum. QCs for dynorphin A (0.375, 12.5 and 20 pg/mL) were prepared by spiking 20 uL
of 3.75 pg/mL, 125 pg/mL, and 200 pg/mL standard solution into 180 uL of pooled mouse

serum. QCs for dynorphin B were prepared in two batches, first batch of QCs (0.25, 2.5
and 25 pg/mL) were prepared by spiking required concentrations of working standard
solution into pooled mouse serum, which was utilized for assessing al validation

parameters except matrix effect. The second batch of QCs (0.375, 12.5 and 20 pg/mL) were

prepared in six different lots of mouse serum by spiking 20 uL of 3.75 pg/mL, 125 pg/mL,
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and 200 pg/mL standard solution into 180 uL of mouse serum. Calibrators for alpha

neoendorphin (5, 7.5, 10, 12.5, 25, 50 pg/mL) were prepared by spiking 20 |1L each of
working standard solution (50, 75, 100, 125, 250 and 500 pg/mL pg/mL) of the peptides

into 180 |iL of pooled mouse serum. QCs for alpha-neoendorphin (10, 25 and 40 pg/mL)
were prepared by diluting 20 uL of 100 pg/mL, 250 pg/mL, and 400 pg/mL standard
solution with 180 uL of pooled mouse serum. Zero calibrator (blank solution) was prepared

by spiking 20 uL of 2% acetonitrile into 180 uL of pooled mouse serum (n=2). These
solutions were further treated as follows to extract the peptides to prepare the final
calibrators and QCs. A volume of 900 uL of 2 % formic acid in ice-cold acetone was added

to 40 uL of spiked mouse serum and shaken at 4°C for 1 h, followed by centrifugation at

17000 g for 15 min at 4°C. The precipitate was separated and 200^L of 70% acetonitrile
(ACN) containing 12 mM HCl was added to the precipitate and mixed at 4°C for 1 h, then

centrifuged at 17000 g for 15 min at 4°C. Low molecular weight proteins and peptides
were extracted into the supernatant, which was then transferred into a separate vial. The

supernatant was then concentrated using a Centrivap cold trap from Labconco and
reconstituted with 40 uL of 0.1% formic acid and 2% acetonitrile in water.
3.2.7 Digestion of the extracted peptide

A Lys-N endopeptidase stock solution was prepared by dissolving the peptidase in
appropriate volume of water to make a 0.1 mg/mL solution. The working solution (500
ng/mL) was prepared by diluting the stock solution with water and stored at -200C.

Digestion buffer (50 mM solution of ammonium bicarbonate and 5 % dimethyl sulfoxide
in water) was freshly prepared before every digestion cycle.
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Extracted peptide was digested by adding 20 uL of the working Lys-N peptidase
solution and 60 uL of digestion buffer to 40 uL of prepared peptide solution (section 3.2.5).

This mixture was stirred and incubated at 300C for 12 hours.

3.2.8 Method validation:
The method thus optimized was validated in mouse serum for accuracy, precision,

selectivity, lower limit of quantification, matrix effect, recovery and stability to determine
its compliance with the limits mentioned in FDA guidelines for bio analytical method
validation.
3.2.8.1

Calibration:
The calibration curves were established by plotting the peak area ratios of

dynorphin A (y) versus the spiked concentrations (x) of the calibration standards for each
of the six calibrators. The slope and correlation coefficient of the calibration curve were

calculated linear least squares regression.
3.2.9 Precision, accuracy and absolute extraction recovery:
Intra-assay (within a day) and inter-assay (3 days) precision and accuracy studies
were conducted using the three QC standards (n = 3). Accuracy was determined by

comparing the concentrations experimentally determined to the concentration of the

prepared QCs.

A mean percent recovery was calculated to assess the effect of extraction process on
the recovery of the analytes by comparing the experimentally determined peak areas of the

peptides post extraction, using pre-extraction spiked QCs standards in serum, with the peak
areas of the QC standards spiked into neat solution.
26

3.2.10

Selectivity, matrix effect and LLOQ:

Six blank serum replicates and six LLOQ serum standards at 0.125 pg/mL were

prepared from six different individual lots of mouse serum to evaluate the matrix
interference and LLOQ.

A matrix factor was calculated to assess the effect of serum components on

dynorphin A, dynorphin B and alpha-neoendorphin. Three QC concentrations were
prepared by post extraction addition of the peptides to six individual lots of mouse serum
as directed in sections 3.2.5. and 3.2.6. The peak area of the QCs spiked post extraction

into serum was compared to the peak area of the QCs in the neat solution.
3.2.11

Stability studies:

Stability studies (n = 3) were done using two different QC concentrations for each of
the three dynorphins which were kept at or exposed to the following storage regimens.

Dynorphin A: 12 h at room temperature, 6 h and 12 h at autosampler temperature.
Dynorphin B: 3 h and 40 h at room temperature, 6 h and 12 h at autosampler temperature

and 60-day stability at -200C. Alpha-neoendorphin: 48 h at room temperature and 6 h and
12 h at autosampler temperature. The stability results of these QC standards were compared

with theoretical values.

3.3 Results
3.3.1 Results for intact dynorphins
Experiments were done on a-Halo Peptide 2 ES-C18 column (50 x 2.1 mm, 2 pm)

(Advanced Material Technology, Chadds Ford, PA, USA), using a mobile phase A of 0.1%
formic acid and 10% acetonitrile in water and a mobile phase B of 0.1% formic acid and
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90% acetonitrile in a gradient specified below, at a flow rate of 0.40 mL/min. The 15 min

gradient run was: 0 % B for 5 min, linear gradient to 90% in 10 min. the column was then

washed for 5 min with 90% B. After the run, the column was re-equilibrated with 100% A
for 10 min. Source parameters for highest signal intensity were as follows: curtain gas 20
psi; ion spray voltage 5200 V; ion spray temperature 400°C; ion source gases (1 and 2) 35
psi; declustering potential 40 V; entrance potential 5 V; collision energy 60 eV and cell
exit potential 15 eV.

Results are given below categorized for each dynorphin.
3.3.1.1 Mass spectrum results for intact dynorphin A

The theoretical mass to charge rations (m/z) were calculated using the amino acid
sequence of dynorphin A and the expected m/z values are shown in Table VI. Three of

these ions are seen in the infusion full spectrum mass spectrum given in Figure 3: m/z of
716.8 (+3), 537.8 (+4) and 430.5 (+5).
Table VI : Expected m/z of intact dynorphin A

Possible dynorphin ions from ESI
Charge state

m/z

+1

2148.5

+2

1074.7

+3

716.8

+4

537.8

+5

430.5
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Figure 3 : Full spectrum scan of intact dynorphin A showing the relative intensities of
detected m/z at an infusion rate of 10 ^L/minute at 10 pg/^L in 15% ACN was infused.
The MS/MS spectra of the parent ions 716.8 (+3), 537.8 (+4) and 430.5 (+5) are

shown in Figures 4, 5 and 6 respectively. A syringe infusion pump at 10 ^L/min of intact

peptides (10 pg/^L) in 0.1% formic acid and 15% acetonitrile in water was introduced, in
order to optimize mass spectrometer parameters. Source parameters for highest signal

intensity were as follows: curtain gas 30 psi; ion spray voltage 3500 V; ion spray
temperature 300°C; ion source gases (1 and 2) 30 psi; declustering potential 35 V; entrance

potential 10 V; collision energy 40 eV and cell exit potential 15 eV.

29

Figure 4 : MS/MS of 430.5 m/z of intact dynorphin A

Figure 5 : MS/MS of 537.8 m/z of intact dynorphin A
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Figure 6 : MS/MS of 716.8 m/z of intact dynorphin A
3.3.1.2 Mass spectrum results for intact alpha-neoendorphin
Preliminary experiments include a full spectrum scan (MS 1 scan) and a MS2 scan

for the most intense m/z of the infused intact peptide. The theoretical mass to charge rations

(m/z) were calculated using the amino acid sequence of the peptide and the expected m/z
values are shown in Table VII.
The resulting MS/MS spectrum of m/z 410.5 and 615.2 are shown in Figure 7 and
Figure 8 respectively. A syringe infusion pump at 10 ^L/min of intact peptides (10 pg/^L)

in 0.1% formic acid and 15% acetonitrile in water was introduced, in order to optimize
mass spectrometer parameters. Source parameters for highest signal intensity were as
follows: curtain gas 40 psi; ion spray voltage 5000 V; ion spray temperature 300°C; ion

source gases 1 and 2 are 15 and 25 psi respectively; declustering potential 28 V; entrance
potential 50 V; collision energy 450 eV and cell exit potential 20 eV.
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Table VII : Theoretical m/z values for alpha neoendorphin
Possible alpha neoendorphin ions from ESI
Charge state

m/z

+1

1229.4

+2

615.2

+3

410.5

Figure 7 : MS/MS spectrum of 410.5 m/z of intact alpha-neoendorphin

Figure 8 : MS/MS spectrum of 615.2 m/z of intact alpha-neoendorphin
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3.3.1.3 LC-MS/MS results of intact dynorphin A and alpha-neoendorphin

Based on the results from the infusion experiments, the combination of the parent

and fragment ions (MRM pair) which gave the highest intensity was selected for both

dynorphin A and alpha-neoendorphin and are given in Table VIII.
Table VIII : MRM pair for dynorphin A and alpha-neoendorphin

Peptide

Q1 m/z

Q3 m/z

dynorphin A

537.8

136

a-neoendorphin

410

91

LC-MS/MS analysis was performed on a Halo peptide C18 column using the
optimized MRM pairs to determine the lower limit of detection (LLOD) and lower limit of
quantification (LLOQ) of dynorphin A and alpha-neoendorphin. Chromatograms showing
the LLOD of both the peptides is given in Figure 9. The LLOD and LLOQ were found to

be 270 pg/mL and 540 pg/mL for dynorphin A and 120 pg/mL and 250 pg/mL for alpha
neoendorphin as given in Table IX.
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Figure 9 : LLOD of dynorphin A and alpha-neoendorphin

Table IX : LLOD and LLOQ of dynorphin A and alpha neoendorphin

Peptide

LLOD
pg/mL

LLOQ
pg/mL

Dynorphin A

270

540

Physiologic
Conc
pg/mL

0.16 to 23.5
aneoendorphin

120

250

LLOD: Lower limit of detection
LLOQ: Lower limit of quantification
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3.3.1.4 LC-MS/MS conditions:

Concerning the chromatography, extensive studies employing different gradients
on two C18 columns were done to optimize the chromatography of dynorphin A and alpha

neoendorphin, however without success in completely resolving the two peptides. Polar
end capped C18 columns such as Aquasil C18 (Thermoscientific, Swedesboro, NJ) (50x1
mm, 3um) was one of the column used and the gradient for chromatography started with

0% mobile phase B for the initial 3 minutes, increased to 15.5 % in 0.5 minutes and then
to 20 % in 6.5 minutes with a gradient time of 20 minutes in total. A 15-minute wash and

equilibration cycle were added after the 20-minute gradient. The overlap of the peptide
peaks is shown in Figure 10 for the polar end capped Aquasil C18 column.

Co-eluting dynorphin A and alpha neoendorphin

------- Alpha neoendorphin

--------Dynorphin A

Figure 10 : Co-elution of dynorphin A (mrm pair: 537.8 - 136; 10pg/uL) and alpha
neoendorphin (mrm pair: 410 - 91; 10 g/^L ) in the LC-MS/MS using an Aquasil C18
column. Injection volume was 20 ^L
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3.3.1.5 .

Discussion of results of intact dynorphins

The results from these experiments gave insight in how the intact peptides respond

to mass spectrometry analysis. The following is concluded:
a. The intact dynorphins were not sensitive to mass spectrometry analysis to determine at
physiologic concentrations

b. Low physiologic concentrations increase the probability of loss of the peptides during
the sample preparation process due to nonspecific binding to high abundant proteins in
the biological matrix and the walls of the consumables leading to a loss of peptide

significantly impacting recovery and reproducibility at such low concentrations.

c. The peptides, co-eluted and thus optimization of chromatography is needed to not only
separate the peptides but also improve sensitivity.
3.3.1.6 Addressing the limitations of intact dynorphin MS analysis

Below is a discussion on what modifications were incorporated in the LCMS/MS technique to achieve specific and sensitive quantification of dynorphins at

physiologic concentrations.
a. Peptide digestion

Digesting a protein/peptide at specific locations of the polypeptide chain based on
the proteolytic enzyme specificity. Trypsin is the most used protease in mass spectrometric

analysis of peptides and proteins. It cleaves the protein or peptide at the C-terminal side of
lysine and arginine amino acid residues. If a proline residue is on the carboxyl side of the

cleavage site, the cleavage will not occur. In case of dynorphins, use of trypsin results in
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very small peptide fragments which is problematic in MRM techniques in terms of

specificity. Fragments that have a longer sequence are more specific for the parent
protein/peptide in MRM analysis . Trypsin cleavage sites in dynorphin B are shown in

Figure 11.

Figure 11 : Trypsin cleavage sites on dynorphin B
To overcome the challenge of generating small nonspecific peptide fragments in

trypsin digestion of dynorphins, a novel peptidase called Lys N was used which cleaves
the peptides/proteins at the N-terminus of lysine, unless lysine is adjacent to a proline. The

expected post digestion peptide fragments of dynorphin A, dynorphin B and alpha
neoendorphin are as shown in Table X. It is noted in Table X that not only are the parent

ions different for these three peptides, but also the daughter ions are different, which yields

further specificity to the MRM technique. Lys-N cleavage site in dynorphin B is shown in

Figure 12, showing the generation of 9 amino acid peptide.
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Figure 12 : Lys-N cleavage sites on dynorphin B
Table X : Expected post digestion peptide fragments of dynorphin A, dynorphin B and
alpha neoendorphin

Peptide

Sequence and cleavage sites

Dynorphin A

YGGFLRRIRPK^KWDNQ

Generated peptides

YGGFLRRIRPKL
KWDNQ

Dynorphin B

YGGFLRRQF^KVVT

YGGFLRRQF
KVVT

a-neoendorphin

YGGFLR^KYPK

YGGFLR

KYPK

b. Use of a column with smaller internal diameter
The in-peak concentration of an analyte is dependent on multiple factors such as
injection volume, length and internal diameter of the column and retention factor. As

shown in the Equation 1 , Cmax increases four-fold when the internal diameter is reduced to

half of the original. Based on this, the 2.1 mm internal diameter column used for the initial
study was changed to a 1 mm internal diameter column.
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r
, JÑVt
^max « Ld2(i+k)

(Equation 1)

Cmax : in-peak concentration

L : length of the column

N : number of plates

dc : diameterk: retention factor

Vi : injection volume
c.

Use of mixed phase column
The reversed phase column that was used for preliminary experiments was replaced

with a polar end-capped reversed-phase column [Luna Omega Polar C18 100 A LC column

(50 x 1 mm, 1.6 pm)] and a multi-step and extended time gradient was developed in place

of a steeper linear gradient which resulted in a baseline of the three dynorphins, as given
in the results.

3.3.2 Results for LC-MS/MS of Lys-N digested dynorphins
3.3.2.1 Digestion and chromatographic separation of dynorphins results

Experimental results of digestion performed on the three peptides showed a deviation in
the expected cleavage pattern for dynorphin A, as shown in Table XI, with the

experimentally determined m/z values given in Table XII.

Table XI : Observed cleavage sites and generated peptides for dynorphin A
Peptide

Sequence and cleavage sites

Dynorphin A

YGGFLRRIR^K^ WDNQ

Generated peptides

YGGFLRRIRP
KL
KWDNQ
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Table XII : Amino acid sequence, charge states and molecular weights of the digested peptide fragments

(red highlighted chosen for analysis)
Peptide

Dynorphin A

Amino acid
sequence

Charge state

YGGFLRRIRP

+3, +2, +1

+3

+2

+1

412.5

618.2

1234.5

KL

+1

259.3

KWDNQ

+1

689.7

YGGFLRRQF

+2, +1

Dynorphin B

Alpha-Neoendorphin

m/z

+2

+1

572.5

1143.5

KVVT

+1

446.5

YGGFLR

+1

712.0

KYPK

+2, +1
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+2

+1

268.83

535.66

The separation of peptides dynorphin A, dynorphin B and alpha neoendorphin on a
Luna Omega Polar C18 100 A LC column is shown in Figure 14.

Figure 13 : Separation of the three peptides dynorphin A YGGFLRRIRP fragment
(m/z 412 >136), dynorphin B YGGFLRRQF fragment (m/z 572.5 >136.1) and
alpha-neoendorphin YGGFLR fragment (m/z 712 >278) on a Luna Omega Polar
C18 100 A LC column (25 ^g/mL; Injection volume: 20 ^L)
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3.3.2.2 Dynorphin A results

3.3.2.2.1 Liquid chromatogram of dynorphin A
Dynorphin A is a 17 amino acid peptide with five basic amino acids. It forms three

fragment peptides after digestion and the retention time of the digested peptide fragment
with 10 amino acids (quantifier) is 9.1 minutes (Figure 15).

Retention time (minutes)

Figure 14 : Chromatogram showing the retention time of dynorphin A YGGFLRRIRP
fragment (m/z 412 ^136) on a Luna Omega Polar C18 100 A LC column
(concentration: 2.5 ^g/mL; Injection volume: 20 ^L )
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3.3.2.2.2 Mass spectrometric detection of dynorphin A

Multiple reaction monitoring (MRM) mode was used for the quantification and
specificity of dynorphin A. The selected precursor-product ion pairs for dynorphin A were
m/z 412 ^136. The mass spectrum of the digested dynorphin A peptide and the ms/ms

spectrum of m/z 412 are shown in Figures 16 and 17 respectively.
Evenm Scan[E+) Ret. Time : |27.427| Scan« : |8223]
Base Peak:412.15Æ,819, 521
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Figure 15 : Infusion mass spectrum of the Lys-N digested fragments of intact dynorphin
A
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Figure 16 : MS/MS of the daughter ions of digested YGGFLRRIRP fragment of intact
dynorphin A
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3.3.2.2.3 Method validation of dynorphin A
a. Calibration plot of dynorphin A

Dynorphin A calibration plot of peak areas of the calibrators versus concentration

of the intact dynorphin brought through the entire sample preparation steps given in
Sections 3.26 and 3.27 using 6 non-zero serum calibrators as shown in Figure 18. The

concentrations of the calibrators are 0.125, 0.25, 0.5, 1.25, 12.5 and 25 pg/mL.
Dynorphin A calibration curve

y = 2975.2x + 6396.3
R2 = 0.9979

9.00E+04
8.00E+04
7.00E+04
6.00E+04
5.00E+04
4.00E+04

3.00E+04
2.00E+04
1.00E+04 ••••■'•
0.00E+00

0

5

15

10

20

25

30

Figure 17 : Calibration plot of intact dynorphin A as measured by the YGGFLRRIRP
fragment (m/z 412 ^136) in three trials (n=3)
d. Lower limit of quantification of dynorphin A
The lower limit of quantitation (LLOQ) was determined as the concentration of
dynorphin A of the lowest calibrator which falls in %CV of 20%. The reproducibility of

six replicates in two batches on two separate days of the 0.125 pg/mL calibrator was
determined to be a percent coefficient of variance (%CV) of 14% and percent mean
relative error was 2% as given in table XIII. The mean peak area of the LLOQ from all the
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replicate analysis was 7.44E+03. The chromatogram for the lowest calibrator concentration

is shown in Figure 19.

Figure 18 : Chromatogram showing the retention time of dynorphin A YGGFLRRIRP
fragment (m/z 412 ^136) at the lowest calibrator concentration
Table XIII : Six replicates of 0.125 pg/mL calibrator in 6 lots of mouse serum

R1

R2

R3

R4

R5

R6

Mean

SD3

0.2

0.1

0.1

0.1

0.1

0.1

0.1

0.0

17

3.1

-16

-9.5

9.8

-16

-2.0

Precision

(% CV)4

MC1
(pg/mL)

Accuracy
(% RE)2

MC1: Measured concentration
% RE2: Percent relative error
SD3: Standard deviation
% CV4: Percent coefficient of variance
R : Replicate
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e. Selectivity of dynorphin A

The selectivity of this method was assessed by any interferents observed at the
retention times and mass transitions of dynorphin A in six individual blank mouse serum

samples. No interferent peak was detected at the same retention time (9.1 minutes) and
mass transitions as that of dynorphin A as illustrated by the representative chromatograms

of a blank serum in Figure 20.

Figure 19 : Chromatogram of the blank serum with MRM set for m/z 412

>136

f. Recovery and matrix effect of dynorphin A

The summarized recovery data of dynorphin A (Table XIV) at three different QC

concentrations and LLOQ in pooled mouse serum indicated that the recovery was
consistent and within the permissible limits of variability.
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Table XIV : Percent recovery and % variance in four concentrations in pooled mouse
serum
Prepared
Concentration

(MPR ± SD)3

%CV2

0.125

89.4 ± 0.94

13.8

0.375

89.8 ± 0.66

11.4

12.5

85.6 ± 2.63

5.79

25

89.9 ± 1.79

4.28

CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)
(MPR ± SD)3: Mean percent recovery ± Standard deviation

The mean matrix factor of dynorphin A across all lots and concentrations was 0.87
± 0.01. The matrix factor (MF) at three QC concentrations from six different lots of mouse

serum is summarized in Table XV.
Peak area post extraction spiked serum samples
Matrix factor (MF) =----------- ---------- —--------— ---------- --------------peak area of the spiked neat solution
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Equation 1

Table XV : Matrix factor (MF) in three concentrations from six different lots of mouse
serum
Nominal Concentration
MF ± SD
Serum
(Pg/mL)

Lot 1

Lot 2

Lot 3

Lot 4

Lot 5

Lot 6

0.375

0.84 ± 0.11

12.50

0.88 ± 0.05

20.00

0.89 ± 0.04

0.375

1.1 ± 0.11

12.50

0.87 ± 0.05

20.00

0.89 ± 0.04

0.375

0.85 ± 0.11

12.50

0.84 ± 0.05

20.00

0.91 ± 0.04

0.375

0.86 ± 0.11

12.50

0.86 ± 0.05

20.00

0.92 ± 0.04

0.375

0.85 ± 0.11

12.50

0.91 ± 0.05

20.00

0.95 ± 0.04

0.375

1.1 ± 0.11

12.50

0.80 ± 0.05

20.00

0.80 ± 0.04

(ME ± SD)1: Matrix Effect ± Standard deviation

48

g. Accuracy and precision of dynorphin A

The data for intra-day accuracy and precision were presented in Table XVI and
inter-day accuracy and precision are presented in Table XVII. Intra-day accuracy and
precision were assessed by three individual replicates of four concentrations on same day

while inter-day accuracy and precision were assessed by three replicates of four

concentrations on three separate days.
Table XVI : Intra-day accuracy and precision for four concentrations with three
replicates on the same day(n=6)

Intra-day accuracy and precision

Nominal
Concentration (pg/ml)

Mean Calculated
Concentration (pg/ml)

SD1

Precision
(% CV)2

Accuracy
(% RE)3

0.125

0.13

0.02

12.24

-3.14

0.375

0.40

0.02

4.03

-7.98

12.5

11.81

0.52

4.42

5.53

20

20.49

0.48

2.34

-2.44

CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)
% RE3: Percent relative error
n: calibrators used in calibration plot)

Table XVII : Inter-day accuracy and precision for four concentrations on three different
days (n=6)
Inter-day accuracy and precision

Nominal
Concentration (pg/ml)

Mean Calculated
Concentration (pg/ml)

SD1

Precision
(% CV)2

Accuracy
(% RE)3

0.125

-0.13

0.01

-10.17

6.29

0.375

-0.39

0.02

-4.00

4.60

12.5

-11.64

0.72

-6.19

-6.85

20

-20.10

0.70

-3.48

0.49

CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)
% RE3: Percent relative error
n: calibrators used in calibration plot)
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h. Stability study of dynorphin A

Stability of the QCs of dynorphin A were assessed by analyzing 1 replicate each at
two different temperatures (RT: -220C and 100C) and the data is summarized in the Table

XVIII. Based on the data, dynorphin A is stable for at least 12 hours at benchtop working
temperature of 40C (samples always placed in ice when working on the benchtop),
autosampler temperature of 10 0C. This data shows that there is a significant loss of the

analyte at room temperature, however the loss is not very significant at any of the working

temperatures ( 40C - 10 0C).

Table XVIII: Stability of dynorphin A at 2 temperatures ( -22 0C, 10oC)
Stability at room temperature ( ~22 0C)
Room temperature
Time

PA of the
lowest QC

PA of the
highest QC

0 Hours

8.96E+03

7.31E+04

12 hours

7.72E+03

5.83E+04

Percent Variance

Lowest QC

Highest QC

-13.88

-20.22

Stability at 10 0C
Percent Variance

Autosampler
Time

PA of the
lowest QC

PA of the
highest QC

0 Hours

9.09E+03

7.63E+04

6 hours

9.00E+03

12 hours

8.87E+03

Lowest QC

Highest QC

7.60E+04

-0.99

-0.39

7.16E+04

-2.42

-6.16
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3.3.2.3 Dynorphin B results

3.3.2.3.1

Liquid chromatogram of dynorphin B

Dynorphin B is a 13 amino acid peptide with 3 basic amino acids. Two peptide
fragments are formed after digestion and the retention time of the digested peptide fragment

with 9 amino acids (quantifier) is 10.7 minutes (Figure 21).
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Figure 20 : Chromatogram showing the retention time of dynorphin B YGGFLRRQF
fragment (m/z 572.5 ^136.1) at the lowest calibrator concentration on a Luna Omega
Polar C18 100 A LC column (Injection volume: 20 ^L )
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3.3.2.3.2

Mass spectrometric detection of dynorphin B

Multiple reaction monitoring (MRM) mode was used for the quantification and
specificity of dynorphin B. The selected precursor-product ion pairs for dynorphin B were
m/z 572.5 ^136.1. Representative mass spectrum of dynorphin B showing m/z of digested

fragment YGGFLRRQF on the top and the ms/ms spectrum of the daughter ion 572.5 on
the bottom in Figure 22.

m/z (Da)
Dynorphin B_msms

7.00E+06
6.00E+06
5.00E+06
4.00E+06
<u

3.00E+06
2.00E+06
1.00E+06
0.00E+00

m/z (Da)

Figure 21 : Infusion mass spectra of dynorphin B showing m/z of Lys-N digested
fragment YGGFLRRQF of dynorphin B on the top and the daughter ion of 572.5 on the
bottom
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3.3.2.3.3

Method validation of dynorphin B

a. Calibration curve of dynorphin B

Dynorphin A calibration plot of peak areas of the calibrators versus concentration

of the intact dynorphin brought through the entire sample preparation steps given in
Sections 3.26 and 3.27 using 6 non-zero serum calibrators as shown in Figure 23. The

concentrations of the calibrators are 0.125, 0.25, 0.5, 1.25, 12.5 and 25 pg/mL

Figure 22 : Calibration plot of intact dynorphin B as measured by the YGGFLRRQF
fragment (m/z 572.5 ^136.1) in three trials (n=3)

b. Lower limit of quantification of dynorphin B
The lower limit of quantitation (LLOQ) was determined as the concentration of
dynorphin A of the lowest calibrator which falls in %CV of 20%. The reproducibility of

six replicates in two batches on two separate days of the 0.125 pg/mL calibrator was
determined to be a percent coefficient of variance (%CV) of 9.2 % and percent mean
relative error was 1.7 % as given in table XIX. The mean peak area of the LLOQ from all
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the replicate analysis was 3.26E+04. The chromatogram for the lowest calibrator

concentration is shown in Figure 24.

Table XIX : Six replicates of 0.125 pg/mL calibrator in 6 lots of mouse serum

MC1
(pg/mL)

R1

R2

R3

R4

R5

R6

Mean

SD3

0.14

0.12

0.14

0.12

0.12

0.12

0.13

0.012

-12

6.8

-12

0.81

5.9

4.2

-1.7

Precision

(% CV)4

9.2

Accurac
y (%

RE)2
MC1: Measured concentration
% RE2: Percent relative error
SD3: Standard deviation
% CV4: Percent coefficient of variance
R : Replicate

c. Selectivity of dynorphin B

The selectivity of this method was assessed by any interferents observed at the
retention times and mass transitions of dynorphin B in five individual blank mouse serum
matrices. A tiny endogenous interferent peak was detected at the same retention time (10.7

minutes) and mass transitions as that of dynorphin B as illustrated by the representative

chromatograms of the blank serum (Figure 25). The mean peak area of the endogenous
interferent from five different individual blank serum injections was found to be 7.3 % of

the mean peak area of dynorphin B at the LLOQ (table XX), which was lower than the

20% limit set by US Food and Drug Administration. The chromatogram representing the
LLOQ is shown in Figure 24.
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Table XX : Selectivity and Lower limit of quantification
Mean Peak Area
(counts)

Ratio

LLOQ1_1

3.26E+04

14

Blank

2.36E+03

Sample Name

Percent

7.3

LLOQ1: Lower limit of quantification

Figure 23 : Chromatogram showing the retention time ofLys-N digestedfragment
dynorphin B YGGFLRRQFfragment (m/z 572.5 ^136.1) at the lower limit of
quantification

Figure 24 : Chromatogram showing the small interferant peak retention time of Lys-N
digestedfragment dynorphin B YGGFLRRQFfragment (m/z 572.5 ^136.1
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d. Recovery and matrix effect of dynorphin B

The summarized recovery data of dynorphin B as shown in Table XXI at three

different QC concentrations and LLOQ in pooled mouse serum indicated that the recovery
was consistent and within the permissible limits of variability.
Table XXI : Percent recovery and % variance in four concentrations from six
different rep licates of pooled mouse serum
Nominal
(MPR ± SD)3
%CV2
Concentration

0.125

91 ± 2.7

2.7

0.5

93 ± 0

0

1.25

101 ± 3.5

3.5

25

85 ± 6.2

6.2

CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)
(MPR ± SD)3: Mean percent recovery ± Standard deviation
The mean matrix factor of dynorphin B across all lots and concentrations was

1.01±0.11. It can thus be inferred from the data that there was a signal enhancement effect

which may be due the presence of an interferant peak at the retention time (10.7 minutes)
of dynorphin B. The matrix factor (MF) at three QC concentrations from six different lots
of mouse serum is summarized in Table XXII.
Peak area post extraction spiked serum samples
Matrix factor (MF} =-----------:---------- —------ :—:---------- :--------------peak area of the spiked neat solution
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Table XXII : Matrix factor (MF) in three concentrations from six different lots of
mouse serum

Serum

Lot 1

Lot 2

Lot 3

Lot 4

Lot 5

Lot 6

Nominal
Concentration

MF ± SD

0.125

1.07 ± 0.13

2.5

1.05 ± 0.13

25

1.01 ± 0.01

0.125

1.01 ± 0.13

2.5

1.12 ± 0.13

25

1.01 ± 0.01

0.125

1.18 ± 0.13

2.5

1.04 ± 0.13

25

1.01 ± 0.01

0.125

0.97 ± 0.13

2.5

0.88 ± 0.13

25

1.0 ± 0.01

0.125

0.89 ± 0.13

2.5

0.83 ± 0.13

25

0.99 ± 0.01

0.125

0.87 ± 0.13

2.5

0.83 ± 0.13

25

0.98 ± 0.01

(ME ± SD)1: Matrix Effect ± Standard deviation
e. Accuracy and precision of dynorphin B
Intraday accuracy and precision were assessed by three replicates of four

concentrations on same day as summarized in table XXIII while inter-day accuracy and
precision were assessed by three replicates of four concentrations on three separate days as

summarized in table XXIV.
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Table XXIII : Intra-day accuracy and precision for four concentrations with three
replicates on the same day(n=6)

Intraday accuracy and precision

Nominal
Concentration (pg/ml)

Mean Calculated
Concentration (pg/ml)

SD1

Precision
(% CV)2

Accuracy
(% RE)3

0.125

0.13

0.01

10.8

-6.93

0.5

0.57

0.01

1.52

-14.0

2.5

2.52

0.07

2.65

-0.67

25

24.6

0.69

2.82

1.60

CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)
% RE3: Percent relative error
n: calibrators used in calibration plot)
Table XXIV : Inter-day accuracy and precision for four concentrations with three
replicates on three different days (n=6)
Inter-day accuracy and precision

Nominal
Concentration (pg/ml)

Mean Calculated
Concentration (pg/ml)

SD1

Precision
(% CV)2

Accuracy
(% RE)3

0.125

0.13

0.00

2.40

-1.73

0.5

0.53

0.02

3.15

-6.63

2.5

2.49

0.01

0.23

0.33

25
24.4
0.85
3.49
2.47
CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)
% RE3: Percent relative error
n: calibrators used in calibration plot)
f. Stability study of dynorphin B
Stability of the QCs of dynorphin B were assessed by analyzing 1 replicate each at

three different temperatures (220C, 100C, -20 0C) and the data is summarized in the Table

XXV. Based on the data, dynorphin B is stable for at least 12 hours at benchtop working
temperature of 40C (samples always placed in ice when working on the benchtop),
autosampler temperature of 10 0C and for 60 days at the storage temperature of -20 0C.
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This data shows that there is a significant loss of the analyte at room temperature, however
the loss is not very significant at any of the working temperatures ( 40C - 10 0C). The data

for the stability of dynorphin B is summarized in table XXV.
Table XXV : Stability of dynorphin B at three temperatures ( ~22 0C, 100C, -200C)

Stability at room temperature ( ~22 0C)
Percent Recovery (loss of
ana yte)

Room temperature
Time

PA of the
lowest QC

PA of the
highest QC

0 hours

7.09E+03

1.61E+05

3 hours

4.29E+03

40 hours

2.09E+03

Lowest QC

Highest QC

1.36E+05

39.49

15.53

6.67E+03

70.52

95.86

Stability at 10 0C
Percent Variability (loss of
analyte)

Autosampler
Time

PA of the
lowest QC

PA of the
highest QC

0 hours

1.53E+03

1.19E+04

6 hours

1.41E+03

12 hours

1.35E+03

Lowest QC

Highest QC

1.13E+04

7.84

5.04

1.14E+04

4.26

0.88

Long term stability (-20 0C)
Calculated Concentrations
Time

Lowest QC

Highest QC

0 hours

0.129

23.2

60 days

0.142

21.5

PA: Peak area
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Percent Variability (loss of
analyte)

Lowest QC

Highest QC

10.08

7.33

3.3.2.4 Alpha-neoendorphin results

3.3.2.4.1 Liquid chromatogram of alpha-neoendorphin

Alpha neoendorphin is a ten amino acid peptide with three basic amino acids. Two
peptide fragments are formed after digestion and the retention time of the digested peptide

fragment with six amino acids (quantifier) is 7.8 minutes as shown in Figure 26.
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Figure 25 : Chromatogram showing the retention time of Lys-N digested alpha
neoendorphin fragment YGGFLR (m/z 712 >278) at the highest calibrator
concentration on a Luna Omega Polar C18 100 A LC column, Injection volume: 20 ^L
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3.3.2.4.2 Mass spectrometric detection alpha-neoendorphin

Multiple reaction monitoring (MRM) mode was used for the quantification and
specificity of alpha neoendorphin. The selected precursor-product ion pairs for alpha

neoendorphin were m/z 712

>278. The infusion mass spectrum of the Lys-N digested

alpha-neoendorphin peptide (YGGFLR) and the ms/ms spectrum of m/z 712 are shown in

Figure 27 and figure 28 respectively.

Alpha neoendorphin parent ion m/z
14000000

Figure 26 : Infusion mass spectra of the Lys-N digested fragments of intact alpha
neoendorphin (YGGFLR: m/z 712)
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MS/MS (m/z 712)
250000

Figure 27 : MS/MS spectrum of the daughter ions of digested YGGFLR (m/z 712)
fragment of intact alpha-neoendorphin
3.3.2.4.3 Method validation of alpha-neoendorphin
a. Calibration plot of alpha-neoendorphin

Alpha-neoendorphin calibration plot of peak areas of the calibrators versus

concentration of the intact alpha-neoendorphin brought through the entire sample
preparation steps given in Sections 3.26 and 3.27 using 6 non-zero serum calibrators as

shown in Figure 29. The concentrations of the calibrators are 5, 7.5, 10, 12, 25 and 50

pg/mL.
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Calibration curve
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Figure 28 : Calibration plot of intact alpha-neoendorphin as measured by the YGGFLR
(m/z 712 >278) in three trials (n=3)

b. Lower limit of quantification of alpha-neoendorphin of alpha-neoendorphin
The lower limit of quantitation (LLOQ) was determined as the concentration of alpha
neoendorphin at the lowest calibrator (5 pg/mL) which falls in %CV of 20%. The
reproducibility of six replicates in two batches on two separate days of the 5 pg/mL

calibrator was determined to be a percent coefficient of variance (%CV) and percent mean
relative error was 13% as given in table XXVI. The chromatogram for the lowest calibrator
concentration is shown in Figure 30.
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Figure 29 : Chromatogram showing the retention time of alpha neoendorphin digested
fragment YGGFLR (m/z 712 >278) at the lower limit of quantification
Table XXVI: Six replicates of 0.125 pg/mL calibrator in 6 lots of mouse serum

MC1
(pg/mL)

Accuracy
(% RE)2

R1

R2

R3

R4

R5

R6

Mean

SD3

5.7

5.7

4.4

4.5

5.8

5.9

-5.3

0.69

13

14

-11

-10

18

18

13

MC1: Measured concentration
% RE2: Percent relative error
SD3: Standard deviation
% CV4: Percent coefficient of variance
R : Replicate
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Precision

(% CV)4

-13

c. Selectivity of alpha-neoendorphin of alpha-neoendorphin

The selectivity of this method was assessed by any interferents observed at the
retention times (7.8 minutes) and mass transitions of alpha-neoendorphin in six individual

blank mouse serum samples. No interferent peak was detected at the same retention time
(7.8 minutes) and mass transitions as that of alpha-neoendorphin A as illustrated by the
representative chromatograms of a blank serum in Figure 31.
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Figure 30 : Chromatogram of the blank serum showing no interferent peak when
analyzed for Lys-N digested fragment YGGFLR of intact alpha-neoendorphin analyzed
for mrm of 712 >278
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i.

Recovery and matrix effect of alpha-neoendorphin
The summarized recovery data of alpha-neoendorphin (Table XXVII) at three

different QC concentrations and LLOQ in pooled mouse serum indicated that the recovery
was consistent and within the permissible limits of variability.
Table XXVII : Percent recovery and % variance in four concentrations in pooled mouse
serum
Nominal
Concentration
(pg/mL)

(MPR ± SD)3

%CV2

40

86.9 ± 0.62

0.01

10

86.7 ± 0.80

0.01

5

82.5 ± 2.62

0.03

CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)

(MPR ± SD)3: Mean percent recovery ± Standard deviation

The mean matrix factor of dynorphin A across all lots and concentrations was 0.84
± 0.41. The matrix factor (MF) at three QC concentrations from six different lots of mouse

serum is summarized in Table XXVIII.
Peak area post extraction spiked serum samples
Matrix factor (MF) =----------- :--------- —------ :—:---------- :--------------peak area of the spiked neat solution
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Table XXVIII : Matrix factor (MF) in three concentrations from six different lots of
mouse serum
Serum

Lot 1

Lot 2

Lot 3

Lot 4

Lot 5

Lot 6

Nominal Concentration
(pg/mL)

MF ± SD

40

0.87 ± 0.15

25

0.88 ± 0.08

10

0.87 ± 0.29

40

0.88 ± 0.15

25

0.97 ± 0.08

10

0.87 ± 0.29

40

0.99 ± 0.15

25

0.89 ± 0.08

10

1.35 ± 0.29

40

0.92 ± 0.15

25

0.99 ± 0.08

10

1.11 ± 0.29

40

1.19 ± 0.15

25

0.81 ± 0.08

10

1.55 ± 0.29

40

1.20 ± 0.15

25

0.81 ± 0.08

10

1.42 ± 0.29

(ME ± SD)1: Matrix Effect ± Standard deviation
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j. Accuracy and precision of alpha-neoendorphin

The accuracy and precision of the method was evaluated by analyzing replicates of
QCs in pooled mouse serum at 5, 10, 25 and 40 pg/mL on the same day (intra-assay) and
3 separate days (inter-assay). The data for intraday-assay accuracy and precision were
presented in Table XXIX and interday-assay accuracy and precision were presented in

Table XXX. Intraday accuracy and precision were assessed by 3 replicates of 4

concentrations on same day while inter-day accuracy and precision were assessed by 3
replicates of 4 concentrations on 3 separate days.

Table XXIX : Intra-day accuracy and precision for four concentrations with three
replicates on the same day(n=6)
Intraday accuracy and precision
Prepared
Concentration (pg/ml)

Mean Calculated
Concentration (pg/ml)

SD1

Precision
(% CV)2

Accuracy
(% RE)3

40

0.13

0.01

0.20

-14.65

25

0.26

0.02

1.64

-8.30

10

0.57

0.01

0.03

-14.82

5

1.18

0.13

0.00

13.45

Table XXX : Inter-day accuracy and precision for four concentrations on three different
______________________________ days (n=6)_______________________________
Inter-day accuracy and precision
Precision Accuracy
Prepared Concentration
Mean Calculated
SD1
Concentration (pg/ml)
(% CV)2
(% RE)3
(Pg/ml)
40
39.56
5.04
12.73
-1.11

25

23.20

1.47

6.33

-7.19

10

9.59

0.99

10.31

-4.13

5

5.33

0.78

14.57

6.62

CV2: Coefficient of variance (Standard deviation (SD)/Mean calculated concentration)
% RE3: Percent relative error

68

k. Stability study of alpha-neoendorphin

Stability of the QCs of alpha-neoendorphin were assessed by analyzing 1 replicate
each at two different temperatures (RT: -220C and 100C) and the data is summarized in the

Table XXXI. Based on the data, dynorphin A is stable for at least 12 hours at benchtop

working temperature of 40C (samples always placed in ice when working on the benchtop),
autosampler temperature of 10 0C. This data shows that there is a significant loss of the
analyte at room temperature, however the loss is not very significant at any of the working

temperatures ( 40C - 10 0C).

Table XXXI: Stability of alpha neoendorphin at 2 temperatures ( ~22 0C, 100C)
Stability at room temperature ( ~25 0Cs)
Room temperature
Time

PA of the
lowest QC

PA of the
highest QC

0 Hours

3.36E+03

4.99E+05

48 hours

1.39E+03

4.27E+05

Percent Variability

Lowest QC

Highest QC

-58.63

-14.43

Stability at 10 0C
Percent Variability

Autosampler
Time

PA of the
lowest QC

PA of the
highest QC

0 Hours

1.74E+03

4.50E+05

6 hours

1.73E+03

12 hours

1.65E+03

Lowest QC

Highest QC

4.41E+05

-0.58

-2.04

4.46E+05

-5.45

-0.90

PA: Peak area
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Chapter IV
Tumor necrosis factor - alpha

4.1. Cytokines - introduction
Cytokines are small proteinaceous signaling molecules, usually less than 80 K Da in size

[137,138]. They are produced by all nucleated cells and function as messengers or local

hormones, regulating a wide range of biological functions such as inflammation and repair,
innate and acquired immunity, hematopoiesis. In the case of inflammation, their action is
pleiotropic in nature, that is they play a key role not only in the initiation and perpetuation
but also the down regulation of the inflammation process [139,140]. Cytokines are
produced in response to both immune and non-immune events. If they are produced as a

response to an immune reaction, they are produced in the effector phase of the immune
response and control the immune and inflammatory responses [141]. Cytokines are divided

into many types, including the hematopoietic family (interleukins), the interferon family
(IFN-a, P, y), the chemokine family, the tumor necrosis family, colony stimulating factors

(GM-CSF, G-CSF, M-CSF), and stem cell factors. These play a vital role in many
physiological processes [140,141]. Current research project would focus on
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proinflammatory cytokines such as IL-ip, IL-6, TNF-a and chemokine CCL-2. The current
chapter would mainly focus on TNF-a. Cytokines are very potent and are present in
extremely low concentrations in the body. The concentration ranges from 1 pg/mL - 10
pg/mL [142,143]

4.1.1. Tumor necrosis factor - alpha (TNF-a):

Tumor necrosis factor alpha (TNF-a) is a pro-inflammatory cytokine which is

pleiotropic in nature. It has a variety of functions including an influence on sleep,
regulation of immune response and immune system homeostasis, apoptosis, cell
proliferation and differentiation [144-146]. It is also important for resistance to infection
and cancers. Human TNF-a exists in two forms; a type II transmembrane protein, and a

mature soluble protein. The TNF-a transmembrane protein is proteolytically cleaved to

yield a soluble, biologically active 157 amino acid protein (17.4 KDa) protein. This protein
binds as a trimer to cell membrane receptors (TNFR-1 and TNFR-2) to exerts many of its

effects by binding [147].
Amino acid sequence of TNF - a:
VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSE
GLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGA

EAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL [148].
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4.2 LC-MS method development
4.2.1

Chemicals

Recombinant human TNF - a standards were purchased from PeproTech (Rocky
Hill, NJ). Modified sequence grade trypsin was purchased from Promega corporation

(Madison, WI), Ammonium bicarbonate (99% analytical grade) from Sigma (Milwaukee,
Wisconsin). LCMS grade acetonitrile was purchased from Fisher scientific (Hampton,
NH). Deionized water was obtained from a nanopore diamond water purification system

from Thermo Scientific.
4.2.2

Instrumentation

A Shimadzu Nexera UHPLC system with two binary LC-30 AD pumps, a
DUG20A3R degasser, SIL-30 AC autosampler, CTO-10AVP column oven and a CBM

20A controller interfaced with an AB SCIEX 5500 QTRAP mass spectrometer with Electro

Spray Ionization probe and a syringe pump has been used for the purpose of quantification.

Instrument operation, acquisition and processing data was performed using AB SCIEX
Analyst software.

4.2.3

Liquid chromatography

A reversed phase chromatographic column was considered for the analysis of TNF

- a. A linear gradient technique at 300C going from 2% mobile phase B to 40% B in 1
minute and 40% to 90% in 10 minutes was utilized for the elution of the digested protein.
Halo Peptide 2 ES-C18 column (Advanced Material Technology, Chadds Ford, PA, USA)

(50 x 2.1 mm, 2 um) with 0.1% formic acid in water as mobile phase A and 0.1% formic

acid in acetonitrile as mobile phase B, pumped at a flow rate of 0.200 mL/min. Post run
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column wash and equilibration has been incorporated in the gradient program. For each

analysis, 10.0 uL of sample was injected into the system by autosampler set at 10°C, and
the gradient time was 20 minutes. A 10-minute equilibration cycles were also included
within the gradient.

4.2.4

Tandem mass spectrometry
The compound and source dependent parameters were optimized for the best signal

intensity and the conditions were as follows: curtain gas: 40 psi; ion spray voltage: 4000

V; ion spray temperature: 400°C; ion source gas 1: 30 psi; ion source gas 2: 20; declustering
potential: 40 V; entrance potential: 10 V; collision energy: 30 eV and cell exit potential:

15 eV.

4.2.5

Preparation of stock and working standard solutions

Stock solution of the protein was prepared by reconstituting the solid TNF - a
standard at room temperature with deionized water to make a 1 mg/mL solution. The stock
solution was aliquoted into 50 protein low bind tubes and stored at -800C. One of the

aliquots was diluted to 0.1 mg/mL using ammonium bicarbonate solution at pH 7.8. Dilute
20 uL of TNF WS with 30 uL of 2 % ACN and add 100 uL of ACN with 2 % FA. Shake

the solution for 5 minutes and centrifuge at 1500 rpm for 1 minute and 2000 rpm for 2

minutes at 40C. Collect the supernatant and add 10 uL of 0.1 % BSA to it. The sample is
then dried under Nitrogen at 300C. The dried sample is reconstituted with 100 uL of

digestion buffer (50 mM ammonium bicarbonate in 10% acetonitrile in water. The solution

is mixed well, and trypsin was added to the solution (protease: protein 1:20). This solution
is Incubated at 370C for 12 hours. After the incubation, the solution was cooled down to
room temperature and 3 uL of 80 % formic acid was added to quench the digestion process.
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This solution is mixed well for 10 seconds. The solution is centrifuged for 30 seconds to

remove any small particulate matter that might be suspended in the solution. The digested
protein solution was diluted using 0.1% formic acid and 2 % acetonitrile in deionized water

for positive mode and 0.05% ammonium hydroxide and 2 % acetonitrile in deionized water
for negative mode mass spectrometry analysis.

4.2.6

Preliminary in-silico experiments:

a. In-silico digestion:

Initial digestion experiments were performed on online proteomics tools such as
ExPASy : SIB Bioinformatics Resource Portal using the sophisticated algorithm for trypsin

digestion [149] which gives the probability of digestion at all the cleavage sites as a percent
value as shown in Figure 32.
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Figure 31: In-silico digested protein showing cleavage sites and
probability
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b. Calculations of theoretical fragmentation pattern
Theoretical fragmentation is important for the optimization of mass spectrometry

parameters. The m/z can be theoretically calculated based on the number of acidic and
basic amino acids in the protein and the mode being used in the mass spectrometry analysis.
The calculated m/z’s are shown in XXXII, Molecular weight of fragments accounting for

alkylation during sample preparation as shown in Table XXXIII. m/z of the Theoretical
fragments in positive mode and negative modes are shown in Table XXXIV and Table

XXXV respectively.
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Table XXXII: Theoretical or calculated molecular weights

Resulting peptide sequence

Number of Cysteines

Weight to be added

Final MW

PVAHVVANPQAEGQLQWLNR

-

-

2227.511

ANALLANGVELR

-

-

1240.425

DNQLVVPSEGLYLIYSQVLFK

-

-

2425.807

GQGCPSTHVLLTHTISR

1

57

1,864.057

PWYEPIYLGGVFQLEK

-

-

1939.241

PDYLDFAESGQVYFGIIAL

-

-

2118.370

Table XXXIII: Molecular weight of fragments accounting for alkylation during sample preparation
Position of
cleavage site

Name of cleaving
enzyme(s)

Resulting peptide sequence
(see explanations)

31

Trypsin

PVAHVVANPQAEGQLQWLNR

Peptide length
[aa]
20

44

Trypsin

ANALLANGVELR

65

Trypsin

82

Peptide mass [Da]

Cleavage
probability

2227.511

79.2 %

12

1240.425

91.8 %

DNQLVVPSEGLYLIYSQVLFK

21

2425.807

100 %

Trypsin

GQGCPSTHVLLTHTISR

17

1807.057

100 %

128

Trypsin

PWYEPIYLGGVFQLEK

16

1939.241

100 %

157

end of sequence

PDYLDFAESGQVYFGIIAL

19

2118.370

-
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Table XXXIV: m/z of the Theoretical fragments in positive mode
Resulting peptide sequence

Cleavage
probability

PVAHVVANPQAEGQLQWLNR

79.2 %

Number of +
charges
2

ANALLANGVELR

91.8 %

DNQLVVPSEGLYLIYSQVLFK

Final MW

m/z

2227.5

1,114.7, 2228.5

1

1240.4

1241.4

100 %

1

2425.8

2426.8

GQGCPSTHVLLTHTISR

100 %

3

1,864.1

622.3 (+3), 933.0
(+2), 1865.1 (+1)

PWYEPIYLGGVFQLEK

100 %

1

1939.2

1940.2

PDYLDFAESGQVYFGnAL

-

0

2118.4

-

Table XXXV: m/z of the Theoretical fragments in negative mode

PVAHVVANPQAEGQLQWLNR

Cleavage
probability
79.2 %

ANALLANGVELR

91.8 %

1

1240.4

1239.4

DNQLVVPSEGLYLIYSQVLFK

100 %

2

2425.8

1211.9 (-2), 2424.8 (-1)

GQGCPSTHVLLTHTISR

100 %

0

1,864.1

-

PWYEPIYLGGVFQLEK

100 %

2

1939.2

968.6

PDYLDFAESGQVYFGnAL

-

3

2118.4

705.13 (-3), 1058.2 (-2),
2117.4 (-1)

Resulting peptide sequence

Number of - charges

Final MW

m/z

1

2227.5

2226.5
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Figure 32 : Deconvoluted chromatogram showing the peak for
one of the digested peptides of TNF-a (pink colored peak)
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4.2.7

Mass spectrometry analysis
A full scan analysis of TNF - a was performed both in positive and negative mode

to confirm the presence the molecule and to optimize the mass spectrometer parameters.

The data from the initial experiments was deconvoluted using an online bioinformatics

software called SKYLINE. The deconvoluted data showed a large peak for one of the
peptides and seven other peptides detected shown in Figure 33 and the expected sequences
of the peak is shown in Figure 34

4.3 Future experiments
4.3.1
a.

Sample preparation

Sample clean up and separation of the protein from other proteins: The peptide

fragments that had very low intensity causing them to be below the threshold of
detection during the initial analysis can be detected by optimizing the sample

preparation and reducing the background interference. This can be done by multiple
ways. A few methods that can be effective are [150]
1. Spin filters MWCO 15 KDa

2. SPE
3. Immunopeptide capture

4. Immunochemistry-based liquid chromatographic separations
5. Capillary electrophoresis/immunochemistry-based separations
6. Antibody flow-based assays

b. Optimizing digestion efficiency: Bottom-up proteomics relies on the generated

fragments after digestion for detecting the protein. Improving/optimizing the digestion
efficiency will improve the sensitivity of the assay as it will generate the maximum
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possible fragments without the loss of protein. This can be done by multiple
experiments such as

1. Analyzing protein at varying temperatures and duration of digestion to determine
the optimal combination of the two parameters.

2. Digesting protein at different trypsin to protein ratio to find the optimal

combination.

4.3.2

LC-MS optimization

a. Optimizing the full scan analysis parameters
b. Generating an MS/MS fragmentation pattern for all the peptides that can be detected

and optimizing the MRM parameters for the peptides.

Optimize the method for biological matrices such as serum and cerebro spinal fluid.
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CHAPTER V

FUTURE DIRECTIONS
Current work has chromatographically separated dynorphin A, Dynorphin B and
alpha neoendorphin successfully. An LC-MS/MS method has been developed and
validated to quantify the standards of dynorphin A, dynorphin B and alpha-neoendorphin

spiked in serum at the low physiological concentrations for dynorphin A and dynorphin B.
This method will be used to analyze and quantify the basal levels of dynorphin A,

dynorphin B and alpha-neoendorphin in a mouse. The method will be further cross
validated in CSF to increase the utility of the method to multiple matrices.

Preliminary work on LC-MS/MS analysis of TNF a has been done and was able to

detect the standards. This method will be optimized and validated in serum and CSF. The
scope for future work will include a complete LC-MS/MS method development and
validation of cytokines TNF a, IL-1a, IL-6 and the chemokine MCP-1/CCL2 in human

serum , which will be cross validated in CSF. Method will be validated for accuracy,
precision,

limit of detection, lower limit of quantification, stability, extraction recovery and matrix
effect following the FDA guidelines for bioanalytical method validation.
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Eventually, chromatography will be optimized to resolve dynorphin A, dynorphin

B, alpha-neoendorphin, TNF a, IL-1a, IL-6 and MCP-1/CCL2 using a single method,
improving the throughput and efficiency for sample analysis. This method will be used to
do a time study in artificially stressed animal models which will establish the effect of

dynorphins on major proinflammatory cytokines and chemokines and thus the process of
inflammation.

82

REFERENCES

[1]

J.E. Pascoe, K.L. Williams, P. Mukhopadhyay, K.C. Rice, J.H. Woods, M.C. Ko,
Effects of mu, kappa, and delta opioid receptor agonists on the function of

hypothalamic-pituitary-adrenal axis in monkeys, Psychoneuroendocrinology. 33

(2008) 478-486. doi:10.1016/j.psyneuen.2008.01.006.

[2]

C. Schwarzer, 30 years of dynorphins - New insights on their functions in
neuropsychiatric

diseases,

Pharmacol.

Ther.

(2009)

123

353-370.

doi:10.1016/j.pharmthera.2009.05.006.

[3]

W. Wittmann, E. Schunk, I. Rosskothen, S. Gaburro, N. Singewald, H. Herzog, C.

Schwarzer, Prodynorphin-derived peptides are critical modulators of anxiety and
regulate neurochemistry and corticosterone, Neuropsychopharmacology. 34 (2009)

775-785. doi:10.1038/npp.2008.142.

[4]

E. Bivehed, R. Strömvall, J. Bergquist, G. Bakalkin, M. Andersson, Region-specific
bioconversion of dynorphin neuropeptide detected by in situ histochemistry and

MALDI

imaging

mass

spectrometry,

Peptides.

87

(2017)

20-27.

doi:10.1016/j.peptides.2016.11.006.
[5]

A. Minokadeh, L. Funkelstein, T. Toneff, S.R. Hwang, M. Beinfeld, T. Reinheckel,
C. Peters, J. Zadina, V. Hook, Cathepsin L participates in dynorphin production in
brain cortex, illustrated by protease gene knockout and expression, Mol. Cell.

Neurosci. 43 (2010) 98-107. doi:10.1016/j.mcn.2009.10.001.

83

[6]

H. Khachaturian, S.J. Watson, M.E. Lewis, D. Coy, A. Goldstein, H. Akil,
Dynorphin immunocytochemistry in the rat central nervous system, Peptides. 3

(1982) 941-954. doi:10.1016/0196-9781(82)90063-8.

[7]

D. Maysinger, V. Höllt, B.R. Seizinger, P. Mehraein, A. Pasi, A. Herz, Parallel
distribution of immunoreactive a-neo-endorphin and dynorphin in rat and human
tissue, Neuropeptides. 2 (1982) 211-225. doi:10.1016/0143-4179(82)90054-3.

[8]

S.R. Vincent, T. Hökfelt, I. Christensson, L. Terenius, Dynorphin-immunoreactive
neurons in the central nervous system of the rat, Neurosci. Lett. 33 (1982) 185-190.
doi:10.1016/0304-3940(82)90249-X.

[9]

S.J. Watson, H. Khachaturian’, L. Taylort, W. Fischlit, A. Goldstein4, H. Akil, Prodynorphin peptides are found-in the same neurons throughout rat brain:

Immunocytochemical

study

(dynorphin/a-neo-

endorphin/neuropeptide/neuroanatonmy), 1983.
[10]

C.R. Neal, S.W. Newman, Prodynorphin Peptide Distribution in the Forebrain of

the Syrian Hamster and Rat: A Comparative Study With Antisera Against

Dynorphin A, Dynorphin B, and the C-Terminus of the Prodynorphin Precursor

Molecule, 1989.
[11]

O. Civelli, J. Douglass, A. Goldstein, E. Herbert, Sequence and expression of the rat

prodynorphin gene, Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4291-4295.
doi:10.1073/pnas.82.12.4291.

84

[12]

I. Nylander, K. Tan-No, A. Winter, J. Silberring, Processing of prodynorphin-

derived peptides in striatal extracts. Identification by electrospray ionization mass
spectrometry linked to size-exclusion chromatography, Life Sci. 57 (1995) 123-129.

doi:10.1016/0024-3205(95)00253-3.
[13]

J.K. Zubieta, Forebrain Opiates, in: Senses A Compr. Ref., Elsevier Inc., 2008: pp.
821-831. doi:10.1016/B978-012370880-9.00199-7.

[14]

E. Weber, C.J. Evans, J.K. Chang, J.D. Barchas, Brain distributions of a-neo-

endorphin and ß-neo-endorphin: Evidence for regional processing differences,
Biochem. Biophys. Res. Commun. 108 (1982) 81-88. doi:10.1016/0006291X(82)91834-4.

[15]

C. Chavkin, Dynorphin-Still an Extraordinarily Potent Opioid Peptide, Mol.
Pharmacol. Mol Pharmacol. 83 (2013) 729-736. doi:10.1124/mol.112.083337.

[16]

R.

Quirion,

Pain,

nociception

and

spinal

opioid

receptors,

Prog.

Neuropsychopharmacol. Biol. Psychiatry. 8 (1984) 571-579. doi:10.1016/02785846(84)90017-4.
[17]

F. Nyberg, I. Christensson-Nylander, L. Terenius, Measurement of Opioid Peptides
in Biologic Fluids by Radioimmunoassay, in: Springer, Berlin, Heidelberg, 1987:

pp. 227-253. doi:10.1007/978-3-642-71809-0_10.
[18]

A.A. Gutstein HB, Opioid analgesics. In: Goodman and Gilman’s The
Pharmacological Basis of Therapeutics (11th ed.), 2006.

85

[19]

W.M. Yaksh TL, The Pharmacological Basis of Therapeutics, in: K.B. Brunton LL,

Chabner BA (Ed.), Pharmacol. Basis Ther., 12th ed., McGraw-Hill, New York,
2011: pp. 481-525.

[20]

A. Goldstein, W. Fischli, L.I. Lowney, M. Hunkapiller, L. Hood, Porcine pituitary
dynorphin:

complete

amino

acid

sequence

of the

biologically

active

heptadecapeptide., Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 7219-7223.
doi:10.1073/pnas.78.11.7219.

[21]

S.M. Hall, Y.S. Lee, V.J. Hruby, Dynorphin A analogs for the treatment of chronic

neuropathic pain, Future Med. Chem. 8 (2016) 165-177. doi:10.4155/fmc.15.164.

[22]

S. V. Gein, Dynorphins in regulation of immune system functions, Biochem. 79

(2014) 397-405. doi:10.1134/S0006297914050034.
[23]

B.M. Sharp, S. Roy, J.M. Bidlack, Evidence for opioid receptors on cells involved

in host defense and the immune system, J. Neuroimmunol. 83 (1998) 45-56.

doi:10.1016/S0165-5728(97)00220-8.
[24]

R.M. Ransohoff, A.E. Cardona, The myeloid cells of the central nervous system

parenchyma, (n.d.). doi:10.1038/nature09615.
[25]

C.C. Chao, G. Gekker, S. Hu, W.S. Sheng, K.B. Shark, D.F. Bu, S. Archer, J.M.

Bidlack, P.K. Peterson, k opioid receptors in human microglia downregulate human
immunodeficiency virus 1 expression, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
8051-8056. doi:10.1073/pnas.93.15.8051.

86

[26]

L.F. Chuang, T.K. Chuang, K.F. Killam, Q. Qui, X.R. Wang, J.J. Lin, H.F. Kung,
W. Sheng, C. Chao, L. Yu, R.Y. Chuang, Expression of kappa opioid receptors in

human and monkey lymphocytes, Biochem. Biophys. Res. Commun. 209 (1995)

1003-1010. doi:10.1006/bbrc.1995.1597.
[27]

D.M.P. Lawrence, W. El-Hamoulyt, S. Archert, J.F. Learyt, J.M. Bidlack,

Identification of c opioid receptors in the immune system by indirect

immunofluorescence (fluorescein/phycoerythrin/arylacetamide/thymocyte), 1995.
[28]

X. Liang, R. Liu, C. Chen, F. Ji, T. Li, Opioid System Modulates the Immune
Function: A Review, n.d.

[29]

J.M. Bidlack, Detection and Function of Opioid Receptors on Cells from the
Immune System, 2000.

[30]

K. Hagi, K. Uno, K. Inaba, S. Muramatsu, Augmenting effect of opioid peptides on

murine

macrophage

activation,

J.

Neuroimmunol.

50

(1994)

71-76.

doi:10.1016/0165-5728(94)90216-X.
[31]

M.R. Ruff, S.M. Wahl, S. Mergenhagen, C.B. Pert, Opiate receptor-mediated

chemotaxis

of

human

monocytes,

Neuropeptides.

5

(1985)

363-366.

doi:10.1016/0143-4179(85)90029-0.
[32]

C.C. Chao, G. Gekker, S. Hu, W.S. Sheng, P.S. Portoghese, P.K. Peterson,
Upregulation of HIV-1

expression in cocultures of chronically infected

promonocytes and human brain cells by dynorphin, Biochem. Pharmacol. 50 (1995)

715-722. doi:10.1016/0006-2952(95)00176-Z.
87

[33]

B.M. Sharp, W.F. Keane, H.J. Suh, G. Gekker, D. Tsukayama, P.K. Peterson,
OPIOID PEPTIDES RAPIDLY STIMULATE SUPEROXIDE PRODUCTION BY

HUMAN POLYMORPHONUCLEAR LEUKOCYTES AND MACROPHAGES,
Endocrinology. 117 (1985) 793-795. doi:10.1210/endo-117-2-793.

[34]

R.L. Davis, D.J. Buck, N. Saffarian, C.W. Stevens, The opioid antagonist, ßfunaltrexamine, inhibits chemokine expression in human astroglial cells, J.

Neuroimmunol. 186 (2007) 141-149. doi:10.1016/j.jneuroim.2007.03.021.
[35]

L. Zhang, T.J. Rogers, K-Opioid Regulation of Thymocyte IL-7 Receptor and C-C

Chemokine Receptor 2 Expression, J. Immunol. 164 (2000) 5088-5093.

doi:10.4049/jimmunol.164.10.5088.
[36]

T. Laughlin, J. Bethea, R. Yezierski, G. Wilcox, Cytokine involvement in

dynorphin-induced allodynia, Pain. 84 (2000) 159-167. doi:10.1016/S03043959(99)00195-5.

[37]

V.K. Shukla, S. Lemaire, Central non-opioid physiological and pathophysiological
effects of dynorphin A and related peptides., J. Psychiatry Neurosci. 17 (1992) 106
119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188423/ .

[38]

K.F. Shen, S.M. Crain, Dynorphin prolongs the action potential of mouse sensory
ganglion neurons by decreasing a potassium conductance whereas another specific
kappa opioid does so by increasing a calcium conductance., Neuropharmacology.
29 (1990) 343-9. http://www.ncbi.nlm.nih.gov/pubmed/1971431 (accessed March

28, 2020).

88

[39]

L. Chen, L.Y. Huang, Protein kinase C reduces Mg2+ block of NMDA-receptor

channels as a mechanism of modulation, Nature. 356 (1992) 521-523.
doi:10.1038/356521a0.

[40]

R. Llinas, J.A. Gruner, M. Sugimori, T.L. McGuinness, P. Greengard, Regulation
by synapsin I and Ca(2+)-calmodulin-dependent protein kinase II of the transmitter

release

in

squid

giant

synapse.,

J.

Physiol.

436

(1991)

257-282.

doi:10.1113/jphysiol.1991.sp018549.
[41]

R.A.

Nichols,

T.S.

Sihra,

A.J.

Czernik,

A.C.

Nairn,

P.

Greengard,

Calcium/calmodulin-dependent protein kinase II increases glutamate and

noradrenaline release from synaptosomes, Nature.

343

(1990) 647-651.

doi:10.1038/343647a0.

[42]

A.I. Faden, Opioid and nonopioid mechanisms may contribute to dynorphin’s
pathophysiological actions in spinal cord injury, Ann. Neurol. 27 (1990) 67-74.
doi:10.1002/ana.410270111.

[43]

S.R. Kelso, T.E. Nelson, J.P. Leonard, Protein kinase C-mediated enhancement of

NMDA currents by metabotropic glutamate receptors in Xenopus oocytes., J.
Physiol. 449 (1992) 705-718. doi:10.1113/jphysiol.1992.sp019110.
[44]

R.M. Caudle, R. Dubner, Ifenprodil blocks the excitatory effects of the opioid
peptide dynorphin 1-17 on NMDA receptor-mediated currents in the CA3 region of
the guinea pig hippocampus, Neuropeptides. 32 (1998) 87-95. doi:10.1016/S0143-

4179(98)90022-1.

89

[45]

L. Guerrini, F. Blasi, S. Denis-Donini, Synaptic activation of NF-KcB by glutamate

in cerebellar granule neurons in vitro, 1995.
[46]

C. Kaltschmidt, B. Kaltschmidt, J. Lannes-Vieira, G.W. Kreutzberg, H. Wekerle,

P.A. Baeuerle, J. Gehrmann, Transcription factor NF-kB is activated in microglia
during experimental autoimmune encephalomyelitis, J. Neuroimmunol. 55 (1994)

99-106. doi:10.1016/0165-5728(94)90151-1.

[47]

T.L. Sahley, D.J. Anderson, M.D. Hammonds, K. Chandu, F.E. Musiek, Evidence
for a dynorphin-mediated inner ear immune/inflammatory response and glutamate-

induced neural excitotoxicity: An updated analysis, J. Neurophysiol. 122 (2019)
1421-1460. doi:10.1152/jn.00595.2018.

[48]

Y.-J. Gao, L. Zhang, R.-R. Ji, Spinal injection of TNF-a-activated astrocytes
produces persistent pain symptom mechanical allodynia by releasing monocyte
chemoattractant protein-1, Glia. 58 (2010) 1871-1880. doi:10.1002/glia.21056.

[49]

Y.J. Gao, L. Zhang, O.A. Samad, M.R. Suter, K. Yasuhiko, Z.Z. Xu, J.Y. Park, A.L.
Lind, Q. Ma, R.R. Ji, JNK-induced MCP-1 production in spinal cord astrocytes

contributes to central sensitization and neuropathic pain, J. Neurosci. 29 (2009)
4096-4108. doi:10.1523/JNEUROSCI.3623-08.2009.

[50]

L. Guan, R. Townsend, T.K. Eisenstein, M.W. Adler, T.J. Rogers, Both T-Cells and

Macrophages Are Targets of k-Opioid-Induced Immunosuppression, Brain Behav.
Immun. 8 (1994) 229-240. doi:10.1006/brbi.1994.1021.

90

[51]

J.S. Foster, R.N. Moore, Dynorphin and Related Opioid Peptides Enhance

Tumoricidal Activity Mediated by Murine Peritoneal Macrophages, J. Leukoc. Biol.

42 (1987) 171-174. doi:10.1002/jlb.42.2.171.
[52]

I.H. Jonsdottir, Neuropeptides and their interaction with exercise and immune
function,

Immunol.

Cell Biol.

78

(2000)

562-570.

doi:10.1111/j.1440-

1711.2000.t01-10-.x.
[53]

J.-S. Han, C.-W. Xie, Dynorphin: Potent analgesic effect in spinal cord of the rat,

Life Sci. 31 (1982) 1781-1784. doi:10.1016/0024-3205(82)90209-0.
[54]

T. Nakazawa, M. Ikeda, T. Kaneko, K. Yamatsu, Analgesic effects of dynorphin-A
and morphine in mice, Peptides. 6 (1985) 75-78. doi:10.1016/0196-9781(85)900798.

[55]

S. Lyrenäs, F. Nyberg, H. Lutsch, B. Lindberg, L. Terenius, Cerebrospinal fluid
dynorphin1-17 and beta-endorphin in late pregnancy and six months after delivery.

No influence of acupuncture treatment, Acta Endocrinol. (Copenh). 115 (1987)
253-258. http://www.ncbi.nlm.nih.gov/pubmed/2885996.

[56]

J. Lai, M.H. Ossipov, T.W. Vanderah, T.P. Malan, F. Porreca, Neuropathic pain: the
paradox

of

dynorphin.,

Mol.

Interv.

1

(2001)

160-7.

http://www.ncbi.nlm.nih.gov/pubmed/14993349 (accessed August 19, 2019).

[57]

K.C. Kajander, Y. Sahara, M.J. Iadarola, G.J. Bennett, Dynorphin increases in the
dorsal spinal cord in rats with a painful peripheral neuropathy, Peptides. 11 (1990)
719-728. doi:10.1016/0196-9781(90)90187-A.
91

[58]

C.M. Handler, E.B. Geller, M.W. Adler, Effect of u-, k-, and 6-selective opioid

agonists on thermoregulation in the rat, Pharmacol. Biochem. Behav. 43 (1992)

1209-1216. doi:10.1016/0091-3057(92)90504-9.
[59]

A.I. Faden, T.P. Jacobs, Dynorphin-related peptides cause motor dysfunction in the
rat through a non-opiate action., Br. J. Pharmacol. 81 (1984) 271-276.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986877/ .

[60]

A.I. Faden, C.J. Molineaux, J.G. Rosenberger, T.P. Jacobs, B.M. Cox, Increased

dynorphin immunoreactivity in spinal cord after traumatic injury, Regul. Pept. 11
(1985) 35-41. doi:10.1016/0167-0115(85)90029-1.
[61]

M.S. Kannan, A.E. Seip, Neurogenic dilatation and constriction of rat superior
mesenteric artery in vitro: mechanisms and mediators, Can. J. Physiol. Pharmacol.
64 (1986) 729-736. doi:10.1139/y86-123.

[62]

G.G.Z. Feuerstein, A.L. Siren, The opioid system in cardiac and vascular regulation
of normal

and hypertensive

states.,

Circulation.

75

(1987) NaN-NaN.

https://pdfs.semanticscholar.org/bcc0/049703d5e9bb540026071a11323e211239d2 .

pdf.
[63]

Role of endomorphin in the mouse brain: Full Text Search Results, (2019).
http://resolver.ebscohost.com/openurl?sid=CAS%3ACAPLUS&coden=69ART5&

genre=article&date=1999&spage=63&epage=67&title=Shokakan+Horumon+(XV

II)%2C+Gut+Hormone+Kanfaransu+Kirokushu%2C+20th%2C+Japan%2C+1999

&stitle=Shokakan+Horumon+(XVII)%2C+Gut+Horm.+Kanfaransu.

92

[64]

A. Inutsuka, A. Inui, S. Tabuchi, T. Tsunematsu, M. Lazarus, A. Yamanaka,
Concurrent and robust regulation of feeding behaviors and metabolism by orexin

Neuropharmacology. 85

neurons,

(2014)

451-460.

doi:10.1016/j.neuropharm.2014.06.015.
[65]

A.L.O. Hebb, S. Laforest, G. Drolet, Chapter 4.9 - Endogenous opioids, stress, and
psychopathology, in: T. Steckler, N.H. Kalin, J.M.H.M. Reul (Eds.), Tech. Behav.
Neural

Sci.,

pp.

2005:

Elsevier,

561-583.

http://www.sciencedirect.com/science/article/pii/S0921070905800318 .

[66]

K.F. Shen, S.M. Crain, Dynorphin prolongs the action potential of mouse sensory

ganglion neurons by decreasing a potassium conductance whereas another specific
kappa opioid does so by increasing a calcium conductance, Neuropharmacology. 29

(1990) 343-349. http://www.ncbi.nlm.nih.gov/pubmed/1971431 .

[67]

T.L. Sahley, D.J. Anderson, M.D. Hammonds, K. Chandu, F.E. Musiek, Evidence
for a dynorphin-mediated inner ear immune/inflammatory response and glutamateinduced neural excitotoxicity: an updated analysis, J. Neurophysiol. 122 (2019)

1421-1460. doi:10.1152/jn.00595.2018.
[68]

Y. Chen, C. Chen, L.Y. Liu-Chen, Dynorphin peptides differentially regulate the

human

k

opioid

receptor,

Life

doi:10.1016/j.lfs.2007.01.018.

93

Sci.

80

(2007)

1439-1448.

[69]

J.-L. Montiel, F. Cornille, B.P. Roques, F. Noble, Nociceptin/Orphanin FQ
Metabolism: Role of Aminopeptidase and Endopeptidase 24.15, J. Neurochem. 68

(2002) 354-361. doi:10.1046/j.1471-4159.1997.68010354.x.

[70]

B. Reed, J.M. Bidlack, B.T. Chait, M.J. Kreek, Extracellular Biotransformation of

ß-Endorphin in Rat Striatum and Cerebrospinal Fluid, J. Neuroendocrinol. 20 (2008)

606-616. doi:10.1111/j.1365-2826.2008.01705.x.
[71]

J. Sandin, I. Nylander, J. Silberring, Metabolism of ß-endorphin in plasma studied
by liquid chromatography-electrospray ionization mass spectrometry, Regul. Pept.

73 (1998) 67-72. doi:10.1016/S0167-0115(97)01065-3.
[72]

C. Sakurada, S. Sakurada, T. Hayashi, S. Katsuyama, K. Tan-No, T. Sakurada,
Degradation of endomorphin-2 at the supraspinal level in mice is initiated by

dipeptidyl peptidase IV: An in vitro and in vivo study, Biochem. Pharmacol. 66
(2003) 653-661. doi:10.1016/S0006-2952(03)00391-5.

[73]

S. Müller, G. Hochhaus, Metabolism of Dynorphin A 1-13 in Human Blood and

Plasma, Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 12 (1995) 1165-1170.

doi:10.1023/A:1016211910107.
[74]

A.M.B.H.L.C.G. Safavi, Purification and characterization of a secreted T cell ß-

endorphin endopeptidase, Adv. Exp. Med. Biol. 402 (1996) 71-79.
[75]

M. Morgan, H.M.D.R. Herath, P.J. Cabot, P.N. Shaw, A.K. Hewavitharana,
Dynorphin A 1-17 biotransformation in inflamed tissue, serum and trypsin solution

analysed by liquid chromatography-tandem mass spectrometry, Anal. Bioanal.
94

Chem. 404 (2012) 3111-3121. doi:10.1007/s00216-012-6406-8.

[76]

I. Lantz, L. Terenius, High enkephalyl peptide degradation, due to angiotensin

converting enzyme-like activity in human CSF, FEBS Lett. 193 (1985) 31-34.

doi:10.1016/0014-5793(85)80073-9.
[77]

B. Reed, Y. Zhang, B.T. Chait, M.J. Kreek, Dynorphin A(1-17) biotransformation
in striatum of freely moving rats using microdialysis and matrix-assisted laser
desorption/ionization mass spectrometry, J. Neurochem. 86 (2003) 815-823.

doi:10.1046/j.1471-4159.2003.01859.x.
[78]

J.Z. Chou, B.T. Chait, R. Wang, M.J. Kreek, Differential biotransformation of

dynorphin A(1-17) and dynorphin A(1-13) peptides in human blood, ex vivo,

Peptides. 17 (1996) 983-990. doi:10.1016/0196-9781(96)00154-4.
[79]

Q. Li, J.-K. Zubieta, R.T. Kennedy, Practical Aspects of in Vivo Detection of
Neuropeptides by Microdialysis Coupled Off-Line to Capillary LC with Multistage

MS, Anal. Chem. 81 (2009) 2242-2250. doi:10.1021/ac802391b.
[80]

C.D.K. Sloan, The Development of Analytical Methods for Investigations of
Dynorphin A 1-17 Metabolism in the Central Nervous System and Peripheral
Tissues and Transport at the Blood Brain Barrier, University of Kansas, 2005.

[81]

E. Bertol, F. Vaiano, M. Borsotti, M. Quercioli, F. Mari, Comparison of
immunoassay

screening

tests

and

LC-MS-MS

for urine

detection

of

benzodiazepines and their metabolites: results of a national proficiency test., J. Anal.
Toxicol. 37 (n.d.) 659-64. doi:10.1093/jat/bkt063.
95

[82]

K. Yücel, S. Abu§oglu, A. Ünlü, Comparison of immunoassay and liquid
chromatography-tandem mass spectrometry methods in the measurement of serum

androstenedione

levels,

Clin.

Lab.

64

(2018)

69-75.

doi:10.7754/Clin.Lab.2017.170612.
[83]

L. Prokai, H.-S. Kim, A. Zharikova, J. Roboz, L. Ma, L. Deng, W.J. Simonsick,
Electrospray ionization mass spectrometric and liquid chromatographic-mass

spectrometric studies on the metabolism of synthetic dynorphin A peptides in brain
tissue in vitro and in vivo, J. Chromatogr. A. 800 (1998) 59-68. doi:10.1016/S0021-

9673(97)01295-8.
[84]

A. Ljungdahl, J. Hanrieder, M. Fälth, J. Bergquist, M. Andersson, Imaging Mass
Spectrometry Reveals Elevated Nigral Levels of Dynorphin Neuropeptides in L-

DOPA-Induced Dyskinesia in Rat Model of Parkinson’s Disease, PLoS One. 6
(2011). doi:10.1371/journal.pone.0025653.

[85]

J. Hanrieder, A. Ljungdahl, M. Fälth, S.E. Mammo, J. Bergquist, M. Andersson, lDOPA-induced Dyskinesia is Associated with Regional Increase of Striatal
Dynorphin Peptides as Elucidated by Imaging Mass Spectrometry, Mol. Cell.
Proteomics. 10 (2011). doi:10.1074/mcp.M111.009308.

[86]

J. Hanrieder, A. Ljungdahl, M. Andersson, MALDI Imaging Mass Spectrometry of
Neuropeptides in Parkinson’s Disease, J. Vis. Exp. (2012). doi:10.3791/3445.

[87]

F. Beaudry, C.E. Ferland, P. Vachon, Identification, characterization and
quantification of specific neuropeptides in rat spinal cord by liquid chromatography

96

electrospray quadrupole ion trap mass spectrometry, Biomed. Chromatogr. 23
(2009) 940-950. doi:10.1002/bmc.1206.

[88]

N.C. Van De Merbel, Protein quantification by LC - MS : a decade of progress

through the pages of Bioanalysis, 11 (2019) 629-644.
[89]

S.B. Breitkopf, S.J.H. Ricoult, M. Yuan, Y. Xu, D.A. Peake, B.D. Manning, J.M.
Asara, A relative quantitative positive/negative ion switching method for untargeted

lipidomics via high resolution LC-MS/MS from any biological source,

Metabolomics. 13 (2017). doi:10.1007/s11306-016-1157-8.
[90]

S. Eliuk, A. Makarov, Evolution of Orbitrap Mass Spectrometry Instrumentation,
(2015). doi:10.1146/annurev-anchem-071114-040325.

[91]

M. Ghaste, R. Mistrik, V. Shulaev, Applications of fourier transform ion cyclotron

resonance (FT-ICR) and orbitrap based high resolution mass spectrometry in
metabolomics

and

lipidomics,

Int.

J.

Mol.

Sci.

17

(2016).

doi:10.3390/ijms17060816.

[92]

Pros and Cons of Three High-Resolution Mass Spec Approaches | Biocompare: The

Buyer’s Guide for Life Scientists, (n.d.). https://www.biocompare.com/Editorial-

Articles/338099-Pros-and-Cons-of-Three-High-Resolution-Mass-SpecApproaches/ (accessed February 7, 2020).

[93]

(No Title), (n.d.). http://web.gps.caltech.edu/~als/IRMS/course-materials/lecture-6-

--mass-analyzers/lecture-6-notes.pdf (accessed February 7, 2020).

97

[94]

A.D. Catherman, O.S. Skinner, N.L. Kelleher, Top Down Proteomics: Facts and

Perspectives, (2014). doi:10.1016/j.bbrc.2014.02.041.
[95]

L.M. Smith, N.L. Kelleher, : N-Kelleher@northwestern Edu, Proteoform: a single

term describing protein complexity The Consortium for Top Down Proteomics NIH
Public Access, Nat Methods. 10 (2013) 186-187. doi:10.1038/nmeth.2369.
[96]

P.B. Pandeswari, V. Sabareesh, Middle-down approach: a choice to sequence and

characterize

proteins/proteomes

by

mass

spectrometry

f,

(2019).

doi:10.1039/c8ra07200k.

[97]

T. Wehr, Top-Down versus Bottom-Up Approaches in Proteomics, (n.d.).

[98]

L. Yuan, M. Zhu, Quantitative Bioanalysis of Proteins by Mass Spectrometry,
Mater. Methods. 5 (2015) 1-10. doi:10.13070/mm.en.5.1332.

[99]

5 Insights: Protein Quantification Using the Surrogate Peptide Method - Waters,

(n.d.).

https://blog.waters.com/5-insights-regarding-protein-quantification-using-

the-surrogate-peptide-method (accessed April 13, 2020).

[100] C. Lopez-Otin, L.M. Matrisian, Emerging roles of proteases in tumour suppression,
Nat. Rev. Cancer. 7 (2007) 800-808. doi:10.1038/nrc2228.

[101] Proteolytic

enzyme

|

enzyme

|

Britannica,

(n.d.).

https://www.britannica.com/science/proteolytic-enzyme (accessed March 9, 2020).

[102] C. Lopez-Otin, J.S. Bond, Proteases: Multifunctional enzymes in life and disease, J.

Biol. Chem. 283 (2008) 30433-30437. doi:10.1074/jbc.R800035200.

98

[103] The

Degradome

Mammalian

Database,

(n.d.).

http://degradome.uniovi.es/dindex.html (accessed March 9, 2020).

[104] A. Laskar, A. Chatterjee, Protease - Revisiting the Types and potential, J.
Biotechnol. 1 (2009) 55-61.

[105] M.B. Rao, A.M. Tanksale, M.S. Ghatge, V. V. Deshpande, Molecular and

Biotechnological Aspects of Microbial Proteases f, Microbiol. Mol. Biol. Rev. 62

(1998) 597-635. doi:10.1128/mmbr.62.3.597-635.1998.
[106] J. Mótyan, F. Tóth, J. Tozsér, Research Applications of Proteolytic Enzymes in

Molecular Biology, Biomolecules. 3 (2013) 923-942. doi:10.3390/biom3040923.
[107] S. Unajak, S. Aroonluke, A. Promboon, Industrial enzyme applications., 2015.
doi:10.1533/9781782421580.

[108] L. Tsiatsiani, A.J.R. Heck, Proteomics beyond trypsin, FEBS J. 282 (2015) 2612

2626. doi:10.1111/febs.13287.
[109] S. Heissel, S.J. Frederiksen, J. Bunkenborg Id, P. H0jrup Id, Enhanced trypsin on a

budget: Stabilization, purification and high-temperature application of inexpensive
commercial

trypsin

for

proteomics

applications,

(n.d.).

doi:10.1371/journal.pone.0218374.

[110] P. Giansanti, L. Tsiatsiani, T.Y. Low, A.J.R. Heck, Six alternative proteases for

mass spectrometry-based proteomics beyond trypsin, Nat. Protoc. 11 (2016) 993
1006. doi:10.1038/nprot.2016.057.

99

[111] D.L. Swaney, C.D. Wenger, J.J. Coon, The value of using multiple proteases for

large-scale mass spectrometry-based proteomics, (n.d.). doi:10.1021/pr900863u.
[112] S. Bischof, J. Grossmann, W. Gruissem, Proteomics and its application in plant
biotechnology, in: Plant Biotechnol. Agric., Elsevier Inc., 2012: pp. 55-65.

doi:10.1016/B978-0-12-381466-1.00004-3.
[113] L. Sleno, The use of mass defect in modern mass spectrometry, J. Mass Spectrom.

47 (2012) 226-236. doi:10.1002/jms.2953.
[114] R. Aebersold, M. Mann, Mass spectrometry-based proteomics, Nature. 422 (2003)

198-207. doi:10.1038/nature01511.
[115] O.J. Pozo, P. Van Eenoo, K. Deventer, H. Elbardissy, S. Grimalt, J. V. Sancho, F.

Hernandez, R. Ventura, F.T. Delbeke, Comparison between triple quadrupole, time
of flight and hybrid quadrupole time of flight analysers coupled to liquid

chromatography for the detection of anabolic steroids in doping control analysis,
Anal. Chim. Acta. 684 (2011) 107-120. doi:10.1016/j.aca.2010.10.045.
[116] A. Vaghela, A. Patel, A. Patel, A. Vyas, N. Patel, Sample Preparation In Bioanalysis:

A Review, Int. J. Sci. Technol. Res. 5 (2016) 5. www.ijstr.org (accessed April 18,

2020).
[117] R. Kong, Lc/MS application in highthroughput ADME screen, Elsevier Inc., 2005.

doi:10.1016/S0149-6395(05)80061-3.

100

[118] S.T. Wu, Z. Ouyang, T. V. Olah, M. Jemal, A strategy for liquid

chromatography/tandem mass spectrometry based quantitation of pegylated protein

drugs in plasma using plasma protein precipitation with water-miscible organic
solvents and subsequent trypsin digestion to generate surrogate peptides for

detection,

Rapid

Commun.

Mass

Spectrom.

25

(2011)

281-290.

doi:10.1002/rcm.4856.

[119] L. Yuan, M. Zhu, Quantitative Bioanalysis of Proteins by Mass Spectrometry,

Mater. Methods. 5 (2015). doi:10.13070/mm.en.5.1332.
[120] Z. Ouyang, M.T. Furlong, S. Wu, B. Sleczka, J. Tamura, H. Wang, S. Suchard, A.

Suri, T. Olah, A. Tymiak, M. Jemal, Pellet digestion: A simple and efficient sample

preparation technique for LC-MS/MS quantification of large therapeutic proteins in
plasma, Bioanalysis. 4 (2012) 17-28. doi:10.4155/bio.11.286.

[121] L. Yuan, M.E. Arnold, A.F. Aubry, Q.C. Ji, Simple and efficient digestion of a

monoclonal antibody in serum using pellet digestion: Comparison with traditional
digestion methods in LC-MS/MS bioanalysis, Bioanalysis. 4 (2012) 2887-2896.

doi:10.4155/bio.12.284.
[122] G. Liu, Y. Zhao, A. Angeles, L.L. Hamuro, M.E. Arnold, J.X. Shen, A novel and

cost effective method of removing excess albumin from plasma/serum samples and

its impacts on LC-MS/MS bioanalysis of therapeutic proteins, Anal. Chem. 86
(2014) 8336-8343. doi:10.1021/ac501837t.

101

[123] H. Zhang, Q. Xiao, B. Xin, W. Trigona, A.A. Tymiak, A.R. Dongre, T. V. Olah,

Development of a highly sensitive liquid chromatography/tandem mass

spectrometry method to quantify total and free levels of a target protein, interferongamma-inducible protein-10, at picomolar levels in human serum, Rapid Commun.
Mass Spectrom. 28 (2014) 1535-1543. doi:10.1002/rcm.6928.
[124] L. Yuan, A.F. Aubry, M.E. Arnold, Q.C. Ji, Systematic investigation of orthogonal

SPE sample preparation for the LC-MS/MS bioanalysis of a monoclonal antibody
after pellet digestion, Bioanalysis. 5 (2013) 2379-2391. doi:10.4155/bio.13.224.

[125] Z. Yang, M. Hayes, X. Fang, M.P. Daley, S. Effenberg, F.L.S. Tse, LC-MS/MS

approach for quantification of therapeutic proteins in plasma using a protein internal
standard and 2D-solid-phase extraction cleanup, Anal. Chem. 79 (2007) 9294-9301.

doi:10.1021/ac0712502.
[126] Q.C. Ji, R. Rodila, E.M. Gage, T.A. El-Shourbagy, A Strategy of Plasma Protein

Quantitation by Selective Reaction Monitoring of an Intact Protein, Anal. Chem. 75

(2003) 7008-7014. doi:10.1021/ac034930n.
[127] Q. Ruan, Q.C. Ji, M.E. Arnold, W.G. Humphreys, M. Zhu, Strategy and its

implications of protein bioanalysis utilizing high-resolution mass spectrometric
detection

of

intact

protein,

Anal.

Chem.

83

(2011)

8937-8944.

doi:10.1021/ac201540t.
[128] J. Palandra, A. Finelli, M. Zhu, J. Masferrer, H. Neubert, Highly specific and

sensitive measurements of human and monkey interleukin 21 using sequential

102

protein and tryptic peptide immunoaffinity LC-MS/MS, Anal. Chem. 85 (2013)

5522-5529. doi:10.1021/ac4006765.
[129] N.L. Anderson, N.G. Anderson, L.R. Haines, D.B. Hardie, R.W. Olafson, T.W.
Pearson, Mass Spectrometric Quantitation of Peptides and Proteins Using Stable
Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), J. Proteome

Res. 3 (2004) 235-244. doi:10.1021/pr034086h.
[130] J.R. Whiteaker, L. Zhao, L. Anderson, A.G. Paulovich, An automated and

multiplexed method for high throughput peptide immunoaffinity enrichment and
multiple reaction monitoring mass spectrometry-based quantification of protein

biomarkers, Mol. Cell. Proteomics. 9 (2010) 184-196. doi:10.1074/mcp.M900254-

MCP200.
[131] L. Yuan, A. Mai, A.F. Aubry, M.E. Arnold, Q.C. Ji, Feasibility assessment of a

novel selective peptide derivatization strategy for sensitivity enhancement for the
liquid

chromatography/tandem mass

spectrometry bioanalysis

of protein

therapeutics in serum, Rapid Commun. Mass Spectrom. 28 (2014) 705-712.
doi:10.1002/rcm.6836.

[132] H. Hahne, F. Pachl, B. Ruprecht, S.K. Maier, S. Klaeger, D. Helm, G. Médard, M.

Wilm, S. Lemeer, B. Kuster, DMSO enhances electrospray response, boosting

sensitivity of proteomic experiments, Nat. Methods. 10 (2013) 989-991.
doi:10.1038/nmeth.2610.

103

[133] J.G. Meyer, E.A. Komives, Charge state coalescence during electrospray ionization

improves peptide identification by tandem mass spectrometry, J. Am. Soc. Mass
Spectrom. 23 (2012) 1390-1399. doi:10.1007/s13361-012-0404-0.
[134] P. Feist, A.B. Hummon, Proteomic challenges: Sample preparation techniques for
Microgram-Quantity protein analysis from biological samples, Int. J. Mol. Sci. 16

(2015) 3537-3563. doi:10.3390/ijms16023537.
[135] H.J. Issaq, T.P. Conrads, G.M. Janini, T.D. Veenstra, Methods for fractionation,

separation and profiling of proteins and peptides, Electrophoresis. 23 (2002) 3048
3061. doi:10.1002/1522-2683(200209)23:17<3048::AID-ELPS3048>3.0.CO;2-L.
[136] W.D. Nes, Protein Purification:

Principles, High-Resolution Methods, and

Applications. Second Edition Edited by Jan-Christer Janson and Lars Rydén
(Uppsala University). John Wiley & Sons: New York. 1988. 695 pp. ISBN 0-471

18626-0., J. Am. Chem. Soc. 121 (1999) 1625-1625. doi:10.1021/ja985637l.
[137] K.F. Chung, Cytokines, in: Asthma COPD, Elsevier Ltd, 2009: pp. 327-341.

doi:10.1016/B978-0-12-374001-4.00027-4.
[138] V.R. Moulton, Cytokines, in: Syst. Lupus Erythematosus Basic, Appl. Clin. Asp.,

Elsevier Inc., 2016: pp. 137-141. doi:10.1016/B978-0-12-801917-7.00017-6.
[139] S. Lata, G.P.S. Raghava, CytoPred: a server for prediction and classification of

cytokines., Protein Eng. Des. Sel. 21 (2008) 279-82. doi:10.1093/protein/gzn006.

104

[140] R. Alam, A brief review of the immune system, Prim. Care - Clin. Off. Pract. 25

(1998) 727-738. doi:10.1016/S0095-4543(05)70084-1.
[141] M.M. Khan, M.M. Khan, Role of Cytokines, in: Immunopharmacology, Springer

International Publishing, 2016: pp. 57-92. doi:10.1007/978-3-319-30273-7_2.
[142] R. Kruse, B. Essen-Gustavsson, C. Fossum, M. Jensen-Waern, Blood concentrations

of the cytokines IL-1beta, IL-6, IL-10, TNF-alpha and IFN-gamma during
experimentally induced swine dysentery, Acta Vet.

Scand.

50 (2008).

doi:10.1186/1751-0147-50-32.

[143] O. Arican, M. Aral, S. Sasmaz, P. Ciragil, Serum levels of TNF-a, IFN-y, IL-6, IL-

8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with
disease

severity,

Mediators

Inflamm.

2005

(2005)

273-279.

doi:10.1155/MI.2005.273.

[144] H.0. Eggest0l, H.S. Lunde, G.T. Haugland, The proinflammatory cytokines TNF-a
and IL-6 in lumpfish (Cyclopterus lumpus L.) -identification, molecular
characterization, phylogeny and gene expression analyses, Dev. Comp. Immunol.
105 (2020) 103608. doi:10.1016/j.dci.2020.103608.

[145] D.B. Dubravec, D.R. Spriggs, J.A. Mannick, M.L. Rodrick, Circulating human
peripheral blood granulocytes synthesize and secrete tumor necrosis factor a, Proc.

Natl. Acad. Sci. U. S. A. 87 (1990) 6758-6761. doi:10.1073/pnas.87.17.6758.
[146] J.M. KRUEGER, J. FANG, P. TAISHI, Z. CHEN, T. KUSHIKATA, J. GARDI,
Sleep: A Physiologic Role for IL-1beta and TNF-alphaa, Ann. N. Y. Acad. Sci. 856
105

(1998) 148-159. doi:10.1111/j.1749-6632.1998.tb08323.x.
[147] H.T. Idriss, J.H. Naismith, TNFa and the TNF receptor superfamily: Structure

function relationship(s), Microsc. Res. Tech. 50 (2000) 184-195. doi:10.1002/1097-

0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.
[148] Recombinant Human TNF-a, (n.d.). https://www.peprotech.com/en/recombinant-

human-tnf- (accessed April 29, 2020).
[149] PeptideCutter,

(n.d.).

https://web.expasy.org/peptide_cutter/peptidecutter_special_enzymes.html
(accessed April 28, 2020).

[150] J.A. Stenken, A.J. Poschenrieder, Bioanalytical chemistry of cytokines - A review,

Anal. Chim. Acta. 853 (2015) 95-115. doi:10.1016/j.aca.2014.10.009.

106

